

## Therapeutic and preventive properties of honey and its bioactive compounds in cancer: an evidence-based review

Sadia Afrin<sup>1†‡</sup>, Shoja M. Haneefa<sup>2†</sup>, Maria J. Fernandez-Cabezudo<sup>3</sup>, Francesca Giampieri<sup>1,4</sup>,  
Basel K. al-Ramadi<sup>2\*§</sup> and Maurizio Battino<sup>1,4,5\*§</sup>

<sup>1</sup>Department of Odontostomatologic and Specialized Clinical Sciences, Sez-Biocibimica, Faculty of Medicine, Università Politecnica delle Marche, Via Ranieri 65, 60100 Ancona, Italy

<sup>2</sup>Department of Medical Microbiology & Immunology, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates

<sup>3</sup>Department of Biochemistry, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates

<sup>4</sup>Nutrition and Food Science Group, Department of Analytical and Food Chemistry, CITACA, CACTI, University of Vigo – Vigo Campus, Vigo, Spain

<sup>5</sup>International Research Center for Food Nutrition and Safety, Jiangsu University, Zhenjiang 212013, People's Republic of China

### Abstract

Despite the much improved therapeutic approaches for cancer treatment that have been developed over the past 50 years, cancer remains a major cause of mortality globally. Considerable epidemiological and experimental evidence has demonstrated an association between ingestion of food and nutrients with either an increased risk for cancer or its prevention. There is rising interest in exploring agents derived from natural products for chemoprevention or for therapeutic purposes. Honey is rich in nutritional and non-nutritional bioactive compounds, as well as in natural antioxidants, and its potential beneficial function in human health is becoming more evident. A large number of studies have addressed the anti-cancer effects of different types of honey and their phenolic compounds using *in vitro* and *in vivo* cancer models. The reported findings affirm that honey is an agent able to modulate oxidative stress and has anti-proliferative, pro-apoptotic, anti-inflammatory, immune-modulatory and anti-metastatic properties. However, despite its reported anti-cancer activities, very few clinical studies have been undertaken. In the present review, we summarise the findings from different experimental approaches, including *in vitro* cell cultures, preclinical animal models and clinical studies, and provide an overview of the bioactive profile and bioavailability of the most commonly studied honey types, with special emphasis on the chemopreventive and therapeutic properties of honey and its major phenolic compounds in cancer. The implications of these findings as well as the future prospects of utilising honey to fight cancer will be discussed.

**Key words:** Honey; Flavonoids; Cancer; Antioxidant activity; Bioavailability; Chemoprevention

### Introduction

Natural honey has been recognised for its medicinal and nutritional properties for more than 2000 years. Based on botanical sources, honey may be classified as floral (from nectar of flowers), non-floral/honeydew (from deposits secreted by the living parts of plants or excreted onto them by sap-sucking

insects) and mixed (nectar and honeydew)<sup>(1,2)</sup>. Depending on the source, the chemical composition varies with different types of honey. Honey is composed mainly of sugars (about 76 %), with fructose being the major monosaccharide, and water (less than 20 %)<sup>(3)</sup>. Honey has been reported to exhibit a broad range of biological properties including anti-bacterial<sup>(4)</sup>,

**Abbreviations:** 5-FU, 5-fluorouracil; Akt, protein kinase B; ATF, activating transcription factor; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma-2; c-PARP, cleaved poly (ADP-ribose) polymerase; CSC, cancer stem cell; Cyto c, cytochrome c; eIF2 $\alpha$ , eukaryotic initiation factor 2 $\alpha$ ; EMT, epithelial-mesenchymal transition; Erk, extracellular signal-regulated kinase; FAK, focal adhesion kinase; Fas, fatty acid synthetase; FasL, fatty acid synthetase ligand; HIF-1 $\alpha$ , hypoxia-inducible factor-1 $\alpha$ ; JNK, c-Jun N-terminal kinase; LC3, light chain 3; MAPK, mitogen-activated protein kinase; MCF-7, Michigan Cancer Foundation-7; MG, methylglyoxal; MMP, matrix metalloproteinase; MNU, 1-methyl-1-nitrosourea; mTOR, mammalian target of rapamycin; Notch1, Notch homolog 1; Nrf2, nuclear related factor 2; PARP, poly (ADP-ribose) polymerase; PC-3, prostate cancer cell line; p-Erk, phosphorylated extracellular signal-regulated kinase; PERK, protein kinase RNA-like endoplasmic reticulum kinase; PI3K, phosphatidylinositol 3-kinase; ROS, reactive oxygen species; STAT3, signal transducer and activator of transcription 3; TGF- $\beta$ , transforming growth factor  $\beta$ ; VEGF, vascular endothelial growth factor; Wnt, wingless-type.

\* **Corresponding authors:** Basel K. al-Ramadi, fax +971 3 767 1966, email Ramadi.b@uaeu.ac.ae; Maurizio Battino, fax +39 71 220 4123, email m.a.battino@univpm.it

† These authors contributed equally to the present study.

‡ Present address: Department of Gynecology and Obstetrics, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA.

§ Co-senior authors.

| Chemical composition of honey (per 100 g) |           |          |              |                                    |          |
|---|-----------|----------|--------------|------------------------------------|----------|
| Proximates                                |           | Minerals |              | Vitamins                           |          |
| Water                                     | 17.1 g    | Na       | 0.0–7.60 mg  | Riboflavin (B <sub>2</sub> )       | 0.38 mg  |
| Energy                                    | 304 kcal  | K        | 13.2–16.8 mg | Niacin (B <sub>3</sub> )           | 0.121 mg |
| Ash                                       | 0.2 g     | Ca       | 4.4–9.20 mg  | Pantothenic acid (B <sub>5</sub> ) | 0.068 mg |
| Dietary fibre                             | 0.2 g     | Fe       | 0.06–1.5 mg  | Vitamin B <sub>6</sub>             | 0.024 mg |
| Proteins                                  | 0.2–1.6 g | Mg       | 1.2–3.5 mg   | Folate (B <sub>9</sub> )           | 2 mg     |
| Amino acid                                | 1 g       | Mn       | 0.02–0.4 mg  | Vitamin C                          | 0.5 mg   |
| Proline                                   | 0.090 g   | P        | 1.9–6.30 mg  | Choline                            | 2.2 mg   |
| Aspartic acid                             | 0.027 g   | Zn       | 0.03–0.4 mg  | Betaine                            | 1.7 mg   |
| Glutamine                                 | 0.018 g   | Cu       | 0.036 mg     |                                    |          |
| Phenylamine                               | 0.011 g   | Se       | 1.0–2.91 µg  |                                    |          |
| Leucine                                   | 0.010 g   | F        | 7 µg         |                                    |          |
| Enzyme (diastase)                         | 1.8 mg    |          |              |                                    |          |
| Sugar                                     | 75–82 g   |          |              |                                    |          |
| Fructose                                  | 28–41 g   |          |              |                                    |          |
| Glucose                                   | 22–35 g   |          |              |                                    |          |
| Maltose                                   | 7.2 g     |          |              |                                    |          |
| Sucrose                                   | 1.5 g     |          |              |                                    |          |
| Galactose                                 | 3.10 g    |          |              |                                    |          |
| Higher sugar                              | 1.5 g     |          |              |                                    |          |
| Other/undetermined sugar                  | 3.2 g     |          |              |                                    |          |
| Organic acid                              | 0.57 g    |          |              |                                    |          |
| Free acid as gluconic                     | 0.43 g    |          |              |                                    |          |
| Lactone as gluconolactone                 | 0.14 g    |          |              |                                    |          |

Fig. 1. Chemical composition of honey according to the United States Department of Agriculture<sup>(15)</sup>. To convert kcal to kJ, multiply by 4.184.

anti-inflammatory<sup>(5,6)</sup>, antioxidant<sup>(7)</sup>, anti-ulcer<sup>(8)</sup> and anti-tumour<sup>(9)</sup> activities. Many studies have shown that the phenolic and flavonoid components of honey are mainly responsible for its biological activities. The phenolic compounds have also been proposed as biomarker compounds for identification of unifloral honeys<sup>(10)</sup>.

There is an increasing trend in the usage of complementary medicines by cancer patients along with standard chemotherapeutic drugs, for reducing chemotherapy-associated side effects, enhancing anti-tumour immunity and improving cancer-related symptoms<sup>(11,12)</sup>. Honey has been used as a part of complementary medicine to treat diverse diseases for many years. However, more recently, there has been an increased interest in the anti-cancer properties of various types of honey because of their different bioactive compounds. Several mechanisms have been reported to explain the anti-cancer or chemoprotective activities of honey, with studies ranging from cell culture to animal models and clinical trials. The present review focuses on the chemical composition and bioavailability of honey and the reported *in vitro*, preclinical and clinical studies with different types of honey in the context of cancer.

### Bioactive profile of honey

The bioactive profile of honey is a complex one to describe since it is a combination of approximately 200 compounds, consisting of different types of sugars, proteins, free amino acids, organic acids, essential minerals, water, enzymes, vitamins, volatile compounds, pigments and a variety of phenolic compounds<sup>(7,13)</sup>.

### Chemical composition of honey

The chemical composition of honey is variable, as already reported<sup>(14)</sup>. These diversities mainly depend on the floral source

and geographical regions together with some external factors, such as seasonal and environmental factors, processing and storing conditions (Fig. 1)<sup>(15)</sup>.

**Sugar in honey.** About 75 % of the sugars present in honey are monosaccharides, fructose (about 40 %) and glucose (about 30 %) being the main components. In addition, 10–15 % are disaccharides, mainly maltose (about 7.20 %), sucrose (about 1.50 %) and small amounts of turanose, isomaltose, maltulose, trehalose, nigerose and kojibiose. The most abundant trisaccharides are maltotriose and melezitose<sup>(7)</sup>. Depending on the analytical technique used for the analysis of various types of honey, different types of disaccharides and trisaccharides have been identified in honey<sup>(16)</sup>. Most of the disaccharides and trisaccharides (sucrose and maltotriose) are enzymically hydrolysed to monosaccharides. For example, sucrose contains one molecule of fructose linked to glucose by  $\alpha$ -1,4 bonding. An equimolar mixture of hexoses is produced by hydrolysing with the enzyme invertase<sup>(17)</sup>. Similarly, maltotriose contains three molecules of glucose units which produce maltose by enzymic hydrolysis. Maltose again converts molecules of glucose by hydrolysing with the enzyme glucosidase<sup>(18)</sup>. The properties and the concentration of sugars in honey mainly depend on the botanical origin (types of flower used by honeybees), geographical origin (climate factors), and processing and storage conditions<sup>(19)</sup>. The ratio between fructose and glucose is a useful marker of the categorisation of monofloral honey. Honey is an important source of energy for the human body as it is easy to digest and its main components (glucose and fructose) are quickly transported to the blood to provide the required energy. Interestingly, 100 g of honey provide 304 kcal (1272 kJ) which is equivalent to 64 kcal (268 kJ) per tablespoon

(21 g)<sup>(15)</sup>. A daily dose of 21 g represents 3 % of the daily recommended energy intake.

**Proteins, amino acids and enzymes in honey.** Depending on the species of honeybee, the content of proteins varies. For example, honey from *Apis cerana* contains 0.1–3.3 % of proteins, whereas honey from *Apis mellifera* contains 0.2–1.6 %<sup>(20)</sup>. Amino acids make up about 1 % (w/w) of honey. Proline is the major amino acid in honey, representing about 50–80 % of the total amino acid content. Usually, proline is created from the salivary discharge of honeybees (*A. mellifera* L.) during the conversion of nectar into honey<sup>(21,22)</sup>. Proline content in honey has been used as an indicator of maturity of honey, and sometimes to check for adulteration with sugars. In pure honey, 180 mg of proline is the minimum accepted value per kg of honey<sup>(23)</sup>. Other amino acids identified in honey are glutamic acid, aspartic acid, glutamine, histidine, glycine, threonine,  $\beta$ -alanine, arginine,  $\alpha$ -alanine, aminobutyric acid, proline, tyrosine, valine, methionine, cysteine, isoleucine, leucine, tryptophan, phenylalanine, ornithine, lysine, serine, asparagine and alanine<sup>(24)</sup>. Honey also contains a small proportion of proteins in the form of enzymes. For example, invertase (sucrase,  $\alpha$ - and  $\beta$ -glucosidases) hydrolyses sucrose into fructose. Invertase present in the honey sustains its activity when honey is ripened. The enzyme diastase ( $\alpha$ - and  $\beta$ -amylases) hydrolyses starch chains into dextrin and maltose. This enzyme is used as an indicator of honey quality: high-quality honeys contain large amounts of diastase. Lastly, glucose oxidase converts glucose into  $\delta$ -gluconolactone, producing gluconic and acid H<sub>2</sub>O<sub>2</sub> (bactericidal properties)<sup>(25)</sup>.

**Organic acids in honey.** All types of honey have minor acidity due to the presence of about 0.57 % of organic acids. These organic acids are produced by the honeybees during the conversion of nectar into honey<sup>(13)</sup>. Organic acids are used as a marker for differentiating the botanical or geographical origin of the honey and are related to the colour, flavour, acidity, pH and electrical conductivity. Moreover, the presence of these acids increases the stability of honey against micro-organisms and are partly associated with bactericidal properties<sup>(7)</sup>. While gluconic acid is the main component, other acids like aspartic acid, butyric acid, citric acid, acetic acid, formic acid, fumaric acid, galacturonic acid, glutamic acid, glutaric acid, glyoxylic acid, 2-hydroxybutyric acid,  $\alpha$ -hydroxyglutaric acid, isocitric acid,  $\alpha$ -ketoglutaric acid, lactic acid, malic acid, malonic acid, methylmalonic acid, 2-oxopentanoic acid, propionic acid, pyruvic acid, quinic acid, shikimic acid, succinic acid, tartaric acid and oxalic acid have also been reported<sup>(13)</sup>.

**Vitamins and minerals in honey.** Honey contains a very small amount of vitamins, most of them belonging to the vitamin B complex, including thiamine (B<sub>1</sub>), riboflavin (B<sub>2</sub>), nicotinic acid (B<sub>3</sub>), pantothenic acid (B<sub>5</sub>), pyridoxine (B<sub>6</sub>), biotin (B<sub>8</sub> or H) and folic acid (B<sub>9</sub>). Vitamin C is also present in honey but its amount is difficult to determine given its instability due to its chemical and enzymic oxidation<sup>(25)</sup>. The mineral content of honey varies from 0.04 to 0.2 % depending of the type of honey. Botanically, honeys can be classified according to their mineral content

which depends on the geographical origin, and the type of soil in which the plant and nectar were found<sup>(13)</sup>. Honey contains several mineral elements of which K is the most abundant, representing one-third of the total minerals identified in honey. Other minerals in honey, present in small quantities, are Na, Fe, Cu, Si, Mn, Ca and Mg<sup>(13)</sup>.

**Aroma and volatile compounds in honey.** The aroma of honey is generated by the complex mixture of various volatile compounds, which may vary depending on the floral or botanical origin, processing and storage conditions. Unifloral honey has a typical aroma of plants because of the presence of specific volatile compounds from the nectars<sup>(26)</sup>. The flavour of honey is a vital quality for its use in the food industry as well as a selection criterion for consumer choice. The most common are *cis*-rose, *trans*-8-*p*-menthan-oxide-1,2-diol and 3,9-epoxy-1-*p*-mentadieno, which have been used as characteristic markers for lemon honey; sulfur compounds, diketones, and alkanes are used as markers for eucalyptus honey; heptanal and hexanal are used as markers for lavender honey; and methyl anthranilate, lilac aldehyde, hotrienol and 1-*p*-menthen-al are markers for citrus honey<sup>(7,13)</sup>.

### Phenolic profile of honey

The phenolic components of honey are secondary metabolites of the plant, biosynthesised mostly for protection against oxidative damage and stress, and transmitted through the nectar to the honey. Two major families of phenolic compounds have been identified in honey: flavonoids and phenolic acids (Table 1)<sup>(27–47)</sup>.

This variability corresponds with the basis of the two major research themes belonging to the study of the phenolic fraction of honey: (i) the evaluation of the overall bioactive properties of honey from diverse geographical or botanical origins; and (ii) the geographical and/or floral origin of honey on the basis of the presence and abundance of one or more specific phenolic compounds, proposed as chemical marker(s) of origin<sup>(9)</sup>.

**Flavonoids in honey.** Flavonoids are the main functional components of honey. They have a C<sub>6</sub>–C<sub>3</sub>–C<sub>6</sub> nuclear structure, linking two benzene rings joined by a pyran ring. Replacement on the rings results in major classes of flavonoids: flavonols, flavones and flavanones. The concentration of flavonoids in honey is about 20 mg/kg and it differs depending on the botanical origin of the honey<sup>(16)</sup>. According to different studies, the major flavonoid compounds identified in honey are: flavonols (quercetin, myricetin, kaempferol); flavones (chrysin, apigenin, luteolin, diosmetin); flavanones (hesperetin, pinocembrin, naringenin); and flavanols (catechin, epicatechin, epigallocatechin, epigallocatechin gallate) (Fig. 2). The highest content of flavonoids is found in manuka honey (a new Zealand monofloral honey), tualang honey (a multifloral honey originating from Malaysia) and buckwheat honey (a monofloral honey derived from various geographical origins), whereas the lowest content is observed in gelam honey and acacia honey<sup>(48)</sup>. The variation usually depends not only on the floral, botanical and



**Table 1.** Most common identified phenolic compounds and antioxidant capacity of studied honeys

| Honeys           | Geographical origin | Floral source   | Flavonoids  | Phenolic acid   | Total antioxidant capacity  | Reference |
|------------------|---------------------|---|---|---|---|-----------|
| Acacia honey     | Malaysia            | Monofloral ( <i>Robinia pseudo acacia</i> L.)         | Catechin<br>Naringenin<br>Kaempferol  | Benzoic acid<br><i>Trans</i> -cinnamic acid   | DPPH (29.98 (SD 6.06) mg AAE/100 g honey)<br>FRAP (82.39 (SD 5.93) mg TE/100 g honey)                             | (27,28)   |
| Astragalus honey | Iran and Turkey     | Heterofloral ( <i>Astragalus microcephalus</i> Willd) | Total polyphenol (198 mg catechin/100 g)  |   | DPPH IC <sub>50</sub> (7.2 mg/ml)   | (29)      |
| Manuka honey     | New Zealand         | Monofloral ( <i>Leptospermum scoparium</i> )          | Quercetin<br>Luteolin<br>Apigenin<br>Kaempferol<br>Isorhamnetin<br>Leptosin<br>Chrysin<br>Pinocembrin<br>Galangin | Gallic acid<br>4-Hydroxybenzoic acid<br>Caffeic acid<br>Syringic acid<br><i>p</i> -Coumaric acid<br><i>trans</i> -Ferulic acid<br><i>trans</i> -Cinnamic acid                         | DPPH (0.06 (SD 0.01) mmol TE/100 g)<br>FRAP (0.14 (SD 0.00) mmol TE/100 g)<br>TEAC (0.22 (SD 0.00) mmol TE/100 g) | (30–32)   |
| Thyme honey      | Greek               | Monofloral ( <i>Thyme vulgaris</i> )                  | Apigenin<br>Chrysin<br>Galangin<br>Kaempferol<br>Luteolin<br>Myricetin<br>Quercetin                               | Protocatechuic acid<br><i>p</i> -Hydroxybenzoic acid<br>Vanillic acid<br>Caffeic acid<br><i>p</i> -Coumaric acid  | ORAC (415 to 692 μmol of TE/kg)   | (33,34)   |
| Pine honey       | Greek               | Monofloral ( <i>Pinus</i> spp.)                       | Not specified   | Protocatechuic acid<br><i>p</i> -Hydroxybenzoic acid<br>Vanillic acid<br>Caffeic acid<br><i>p</i> -Coumaric acid  | ORAC (712 to 2068 μmol of TE/kg)  | (33)      |
| Fir honey        | Greek               | Monofloral ( <i>Abies cephalonica</i> )               | Not specified   | Protocatechuic acid<br><i>p</i> -Hydroxybenzoic acid<br>Vanillic acid<br>Caffeic acid<br><i>p</i> -Coumaric acid  | ORAC (619 to 2129 μmol of TE/kg)  | (33)      |
| Chestnut honey   | Turkey              | Monofloral ( <i>Castanea sativa</i> )                 | Genistein<br>Pyrogallol<br>Chrysin<br>Apigenin<br>Naringenin<br>Kaempferol<br>Luteolin<br>Hesperetin<br>Rutin     | 4-Hydroxybenzoic acid<br>Gentisic acid<br>3,4-Dihydroxybenzoic acid<br><i>p</i> -Coumaric acid<br>Vanillic acid<br>Homogentisic acid<br>Caffeic acid<br>Ferulic acid<br>Syringic acid | DPPH IC <sub>50</sub> (61.90 (SD 1.07) μg/ml)<br>ABTS IC <sub>50</sub> (12.68 (SD 0.47) μg/ml)                    | (35)      |

Honey and cancer

Table 1. Continued

| Honeys        | Geographical origin | Floral source                              | Flavonoids   | Phenolic acid  | Total antioxidant capacity   | Reference  |
|---------------|---------------------|--|--|--|--|------------|
| Pine honey    | Turkey              | Monofloral ( <i>Marchalina hellenica</i> ) | Genistein<br>Pyrogallol<br>Chrysin<br>Apigenin<br>Naringenin<br>Kaempferol<br>Luteolin<br>Hesperetin<br>Rutin              | 4-Hydroxybenzoic acid<br>Gentisic acid<br>3,4-Dihydroxybenzoic acid<br><i>p</i> -Coumaric acid<br><i>trans</i> -2-Hydroxycinnamic acid<br>Homogentisic acid<br>Vanillic acid<br>Homogentisic acid<br>Caffeic acid<br>Ferulic acid<br>Syringic acid | DPPH IC <sub>50</sub> (67.47 (SD 0.89) µg/ml)<br>ABTS IC <sub>50</sub> (19.12 (SD 0.75) µg/ml) | (35)       |
| Cedar honey   | Turkey              | Monofloral ( <i>Cedrus libani</i> )        | Genistein<br>Chrysin<br>Apigenin<br>Naringenin<br>Kaempferol<br>Luteolin<br>Hesperetin<br>Rutin                            | 4-Hydroxybenzoic acid<br>Gentisic acid<br>3,4-Dihydroxybenzoic acid<br><i>p</i> -Coumaric acid<br><i>trans</i> -2-Hydroxycinnamic acid<br>Vanillic acid<br>Homogentisic acid<br>Caffeic acid<br>Ferulic acid<br>Syringic acid                      | DPPH IC <sub>50</sub> (59.46 (SD 0.99) µg/ml)<br>ABTS IC <sub>50</sub> (11.04 (SD 0.94) µg/ml) | (35)       |
| Gelam honey   | Malaysia            | Monofloral ( <i>Melaleuca</i> spp.)        | Myricetin<br>Catechin<br>Quercetin<br>Hesperetin<br>Chrysin  | Galic acid<br>Chlorogenic acid<br>Caffeic acid<br><i>p</i> -Coumaric acid<br>Ferulic acid<br>Ellagic acid<br>Coniferic acid  | DPPH (50.17 (SD 5.54) mg AAE/100 g honey)<br>FRAP (82.53 (SD 5.03) mg TE/100 g honey)          | (27,28,36) |
| Nenas honey   | Malaysia            | Monofloral ( <i>Ananas comosus</i> spp.)   | Rutin<br>Quercetin<br>Hesperetin   | Chlorogenic acid<br>Caffeic acid<br><i>p</i> -Coumaric acid<br>Ellagic acid  | DPPH % (28.67 (SD 0.95) g/ml)<br>FRAP (311.4 (SD 7.97) g/ml)                                   | (36)       |
| Polish honey  | Poland              | Heterofloral                               | Galic acid<br><i>p</i> -Coumaric acid<br>Ferulic acid<br>Syringic acid<br>Caffeic acid<br>Synapic acid<br>Chlorogenic acid | Quercetin<br>Kaempferol<br>Hesperetin<br>Naringenin<br>Chrysin<br>Galangin   | DPPH % (36.38 (SD 1.47))<br>ABTS % (35.48 (SD 1.07))   | (37)       |
| Kelulut honey | Malaysia            | Multifloral ( <i>Acacia mangium</i> )      | Catechine<br>Apigenin<br>Chrysin<br>Kaempferol<br>4-Hydroxybenzoic acid  | Galic acid<br>Caffeic acid<br>Caffeic acid phenethyl ester<br>Syringic acid<br>Cinnamic acid<br>2-Hydroxycinnamic acid<br><i>p</i> -Coumaric acid<br>Quercetin-3-O-rutinoside  | ABTS (176.66 to 231.5 µmol TE/g)<br>ORAC (30.62 to 83.72 µmol TE/g)                            | (38)       |



Table 1. Continued

| Honeys                     | Geographical origin | Floral source  | Flavonoids  | Phenolic acid  | Total antioxidant capacity   | Reference |
|----------------------------|---------------------|--|---|--|--|-----------|
| Indian honey               | India               | Heterofloral   | Total flavonoids (4.32 to 10.10 mg quercetin/100 g)   | Di-hydroxybenzoic acid<br>Caffeic acid<br>Ferulic acid<br>Cinnamic acid  | DPPH IC <sub>50</sub> (7.33 to 33.50 mg/ml)<br>FRAP (177.4 to 315.8 μM Fe(II))                                 | (39)      |
| Tualang honey              | Malaysia            | Multifloral ( <i>Kompassia excelsa</i> )   | Myricetin<br>Naringenin<br>Hesperetin<br>Kaempferol   | Gallic acid<br>Chlorogenic acid<br>Benzoic acid  | DPPH (9.65 (SD 0.57) mg AAE/100 g honey)<br>FRAP (52.39 (SD 5.19) mg TE/100 g honey)                           | (27,28)   |
| Heather and rosemary honey | Spanish             | Heterofloral   | Kaempferol<br>Chrysin<br>Pinocembrin<br>Galangin<br>Myricetin                                   | Gallic acid<br>Ellagic acid<br>Protocatechuic acid<br>Syringic acid<br>Benzoic acid<br>4-Hydroxybenzoic acid<br>Vanillic acid<br>Caffeic acid<br><i>p</i> -Coumaric acid<br>Ferulic acid<br>Phenyl acetic acid | DPPH IC <sub>50</sub> (17.51 mg/ml)  | (40–42)   |
| Strawberry tree honey      | Italy               | Monofloral ( <i>Arbutus unedo</i> L.)  | Apigenin<br>Galangin<br>Kaempferol<br>Luteolin<br>Pinobanksin<br>Pinocembrin<br>Rutin           | 2- <i>cis</i> ,4- <i>trans</i> Abscisic acid<br>Cinnamic acid  | DPPH (0.20 (SD 0.01) mmol TE/100g)<br>FRAP (0.54 (SD 0.00) mmol TE/100g)<br>TEAC (0.39 (SD 0.01) mmol TE/100g) | (32,43)   |
| Ulmo honey                 | Chile               | Monofloral ( <i>Eucryphia cordifolia</i> Cav.)   | Not specified   | Benzoic acid<br>Cinnamic acid<br>Vanillic acid<br><i>p</i> -Coumaric acid  | DPPH (87.14 (SD 1.13) μmol of TE/g)  | (44)      |
| Coriander honey            | Egypt               | Monofloral ( <i>Coriandrum sativum</i> L.)   | Myricetin<br>Liquiritigenin<br>Eriodictyol<br>Luteolin<br>Quercetin<br>Naringenin<br>Kaempferol | Vanillic acid<br>3,4-Dihydroxybenzoic acid<br><i>Cis-p</i> -Coumaric acid  | DPPH (23.9 %)  | (45)      |
| Jungle honey               | Nigeria             | Heterofloral ( <i>Pentaclethra macrophylla</i> , <i>Chrysophyllum albidum</i> , <i>Milicia excelsa</i> ) | Apigenin<br>Total polyphenols (59.86 to 72.41 mg GAE/100 g)                                     |  | FRAP (417.36 to 668.53 μM Fe(II)/100 g)  | (46,47)   |

AAE, ascorbic acid equivalents; ABTS, 2,2'-azino-bis (3-ethylbenzothiazoline-6-sulphsulfonic acid); DPPH, 2,2-diphenyl-1-picrylhydrazyl radical; GAE, gallic acid equivalents; FRAP, ferric-reducing antioxidant power; IC<sub>50</sub>, half maximal inhibitory concentration (at the maximum concentration of honey in water, 45 g/l); ORAC, oxygen radical absorbance capacity; TE, Trolox equivalents; TEAC, Trolox equivalent antioxidant capacity.

Honey and cancer




Fig. 2. Main classes of honey flavonoids with their chemical structures.





Fig. 3. Main classes of honey phenolic acids with their chemical structures.



**Fig. 4.** Schematic depiction of the absorption and metabolism of honey polyphenols in the human gut. CBG, cytosolic  $\beta$ -glucosidase; LPH, lactase-phlorizin hydrolase; SGLT, sodium-glucose co-transporter; UGT, UDP-glucuronosyltransferase. For a colour figure, see the online version of the paper.

geographical origins, but also on the HPLC method used to determine these compounds<sup>(49)</sup>.


**Phenolic acids in honey.** The phenolic acids of honey can be divided, based on their chemical structure, into two subgroups: hydroxybenzoic acids and hydroxycinnamic acids. All hydroxybenzoic acids share a C1–C6 nuclear structure, derived from benzoic acid, but they differ in the hydroxylation and methylation of the aromatic ring<sup>(13)</sup>. The most common hydroxybenzoic acids found in honey are benzoic acid, vanillic acid, syringic acid, salicylic acid, gallic acid and ellagic acid (Fig. 3). Hydroxycinnamic acids usually share the nuclear structure C3–C6 and exhibit differences in the original rings (phenylacetic acids and acetophenones). The major identified hydroxycinnamic acids in honey are caffeic acid, *p*-coumaric acid, ferulic acid and sinapic acids (Fig. 3). Other phenolic acids such as *p*-hydroxycinnamic acids and chlorogenic acid could also be present in honey, depending on the botanical origins<sup>(7,13)</sup>.

### Bioavailability and metabolites of honey

From a nutritional point of view, bioavailability is the fraction of a nutrient present in a food that is absorbed, retained and used for physiological functions through normal pathways. It is well established from animal and human studies that ingested phenolic compounds (from food sources) survive digestion in the upper digestive tract and reach different parts of the proximal and distal intestine in substantial doses. During the absorption process, phenolics are conjugated (usually methylated, sulfated and glucuronidated) in the small intestine and later in the liver, a metabolic detoxification process that facilitates biliary and urinary elimination. The colonic epithelium is in contact with both the parent and degraded phenolic compounds, which are widely metabolised to simpler phenolics by colonic microbiota and their metabolites can then be detected in urine, faeces, blood and tissue (Fig. 4)<sup>(50)</sup>.

The sequence of absorption and quick elimination of phenolic compounds produces the final plasma concentration of





**Fig. 5.** Chemopreventive effects of honey against different types of cancer both in *in vitro* and *in vivo* models by targeting diverse mechanism of actions. Akt, protein kinase B; Apaf-1, apoptotic protease activating factor-1; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma-2; CDK, cyclin-dependent kinase; COX-2, cyclooxygenase 2; c-PARP, cleaved poly (ADP-ribose) polymerase; cyto c, cytochrome c; EGFR, epidermal growth factor receptor; Erk, extracellular signal-regulated kinase; ESR1, oestrogen receptor 1; FasL, fatty acid synthetase ligand; HO-1, haeme oxygenase 1; IFN-γ, interferon-γ; IFNGR1, interferon-γ receptor 1; MMP, matrix metalloproteinase; Nrf2, nuclear related factor 2; p-IκBα, phosphorylated inhibitor of κB; ROS, reactive oxygen species; SOD, superoxide dismutase; STAT3, signal transducer and activator of transcription 3; VEGF, vascular endothelial growth factor; Wnt, wingless-type. For a colour figure, see the online version of the paper.

oligomeric flavonoids of 1 μmol/l and flavanones of 5 μmol/l. In the case of phenolic acids, bioavailability is much lower due to the esterification process<sup>(50,51)</sup>. Up to date, only one study investigated the bioavailability of buckwheat honey polyphenols in healthy human subjects. Two types of buckwheat honey at 1.5 mg/kg (containing 0.796 and 1.716 mg phenolic antioxidants per g) were supplemented in forty subjects. The total phenolic content along with the antioxidant and reducing capacities of plasma significantly increased 2 h after the honey supplementation and remained high for up to 6 h<sup>(52)</sup>. This investigation supports that the phenolic compounds of honey are not only bioavailable but also exhibit attractive antioxidant activity for inducing defensive mechanisms against oxidative stress. In another study, bioaccessibility and bioavailability of bracinga (*Mimosa scabrella* Bentham) honeydew honey were investigated after simulated *in vitro* digestion. The stability of phenolic constituents and minerals was the highest and, sometimes, increased further after *in vitro* digestion, while the antioxidant capacity was decreased. This finding suggests that honey components other than phenolic and mineral compounds have the ability to affect the antioxidant capacity<sup>(53)</sup>.

### Studies on honey in cancer: mechanisms of chemoprevention

Numerous studies have examined the possible mechanisms by which honey exerts its chemoprevention and concluded that the preventive effects of honey depend on the presence of diverse antioxidant constituents as well as phenolic acids and flavonoids<sup>(48)</sup>.

Diverse *in vitro* models have evaluated the efficiency of whole honey, flavonoid or phenolic extracts, or fractionated honey extracts on different types of cancer<sup>(32,48,54-56)</sup>. Particular attention was given to the key mechanism of the anti-proliferative effect, induction of apoptosis, modulation of oxidative stress, as well as the anti-inflammatory, immunomodulatory and anti-metastatic effects (Fig. 5 and Table 2<sup>(54-83)</sup>).

#### Anti-proliferative effects

The anti-proliferative effect of acacia honey was evaluated on non-small lung cancer (NCI-H460)<sup>(54)</sup> and melanoma (A375 and B16-F1) cell lines<sup>(57)</sup>. Honey treatment arrested the cell cycle at the G0/G1 phase and decreased the mRNA levels of B-cell



**Table 2.** Inhibitory effects of honey or its extract on cancer cell lines *in vitro*

| Honeys                                     | Model (cell lines or animal)   | Duration and dose/intervention                                  | Effects on cancer   | References |
|--|--|---|---|------------|
| Anti-proliferative effects<br>Acacia honey | NCI-H460 non-small lung cancer cells   | 0.5–8 % (w/v) for 48 h  | ↓ Cell viability<br>↓ Bcl-2, p53<br>Arrest cell cycle at G0/G1 phase  | (54)       |
|  | A375 and B16-F1 melanoma cells   | 0.01–0.2 g/ml for 24–72 h                                       | ↓ Cell viability<br>Arrest cell cycle at G0/G1 phase  | (57)       |
| Astragalus honey                           | HepG2 hepatic cancer cells<br>5637 Bladder cancer cells                                      | 0.8–6.25 % (w/v) for 24 h                                       | ↓ Cell viability<br>↓ Bcl-2   | (58)       |
| Manuka honey                               | CT-26 colon cancer cells<br>MCF-7 breast cancer cells<br>B16-F1 melanoma cancer cells        | 0.3–5 % for 24–72 h   | ↓ Cell viability<br>↑ Apoptosis<br>↓ Tumour growth <i>in vivo</i>   | (55)       |
| Manuka honey; manuka honey + 5-FU          | HCT-116 and LoVo colon cancer cells  | 10–20 and 30–40 mg/ml for 48 h<br>5–15 and 20–30 mg/ml for 48 h | ↑ Synergy with paclitaxel<br>↓ Cell viability<br>↓ Arrest cell cycle at S and G2/M phases<br>↓ Cyclin D1, cyclin E, CDK2, CDK4<br>↑ p21, p27<br>↓ EGFR-Her2, p-Akt<br>↑ p-p38MAPK, p-Erk1/2 signalling<br>↑ Synergistic effects | (30,59)    |
| Manuka honey                               | MDA-MB-231 and MCF-7 breast cancer cells   | 0.25–2 % (w/v) for 24–72 h                                      | ↓ Cell viability<br>↓ STAT3 phosphorylation<br>↓ IL-6 production  | (56)       |
| Greek honey extract                        | PC-3 prostate cancer cells<br>MCF-7 breast cancer cells<br>Ishikawa endometrial cancer cells | 0.2–125 µg/ml for 48 h  | ↓ Cell viability<br>↓ Oestrogenic effects   | (60)       |
| Anatolian honey                            | Prostate (PC-3) and breast (MCF-7) cancer cells  | 20–500 µg/ml for 48 h   | ↓ Cell viability  | (33)       |
|  | MCF7, SKBR3 and MDAMB-231 breast cancer cells  | 1–10 µg/ml for 24–72 h  | ↓ Cell proliferation  | (61)       |
| Gelam and nenas honey                      | HT-29 colon cancer cells   | 10–150 (w/v) for 24 h   | ↓ Cell viability<br>↑ DNA damage<br>↓ PGE <sub>2</sub>  | (62)       |
| Gelam honey + ginger extract               | HT-29 colon cancer cells   | 40–80 mg/ml (honey) + 2.5–7.5 mg/ml (ginger) for 24 h           | ↓ Cell viability<br>↓ Kras-Erk, PI3K-Akt signalling   | (63)       |
|  | HT-29 colon cancer cells   | 12.5–400 mg/ml (honey) + 0.0625 to 4.0 mg/ml (ginger) for 24 h  | ↓ Cell viability<br>↓ Wnt/β-catenin signalling  | (64)       |
| Gelam honey + 5-FU                         | HCT-116 colon cancer cells   | 10–110 mg/ml for 24–72 h  | ↓ Cell viability<br>↑ Apoptosis   | (65)       |
| Polish honey                               | U87MG glioblastoma cells   | 0.5–7.5 % for 24–72 h   | ↓ Cell viability<br>↓ DNA synthesis   | (66)       |
| Induction of apoptosis<br>Acacia honey     | PC-3 prostate cancer cells   | 2–10 % (v/v) for 48 h   | Arrest cell cycle at G0/G1 phase  | (67)       |
|  | NCI-H460 non-small lung cancer cells   | 0.5–8 % (w/v) for 48 h  | ↓ TNF-α, IL-1β, Ca ion  | (54)       |
|  | MCF-7 breast cancer cells  | 3.12–100 % (v/v) for 24–72 h                                    | ↓ Cell viability<br>↑ Apoptotic cell death  | (68)       |

Honey and cancer

**Table 2.** *Continued*

| Honeys                                     | Model (cell lines or animal)                              | Duration and dose/intervention                                  | Effects on cancer   | References |
|--|---|---|---|------------|
| Manuka honey, manuka honey + 5-FU          | HCT-116 and LoVo colon cancer cells                       | 10–20 and 30–40 mg/ml for 48 h<br>5–15 and 20–30 mg/ml for 48 h | ↑ p53, caspase-3, 8, 9, c-PARP1, Bax, Cyto C, FasL<br>↓ Bcl2  | (30,59)    |
| Strawberry tree honey                      | HCT-116 and LoVo colon cancer cells                       | 3–12 and 10–40 mg/ml for 48 h                                   | ↑ Synergistic effects<br>↑ p53, caspase-3, -8, -9, c-PARP1, Bax, Cyto C, FasL<br>↓ Bcl  | (69)       |
| Manuka honey                               | MDA-MB-231 and MCF-7 breast cancer cells                  | 0.25–2 % (w/v) for 24–72 h                                      | ↑ Caspase-3/7, -6, -8, -9<br>↑ Bax, Cyto C<br>↓ Bcl-2   | (56)       |
| Manuka honey, manuka honey + drug          | B16-F1 melanoma cancer cells                              | 0.3–5 % for 24–72 h   | ↑ Caspase-3/7, -9<br>↓ Bcl-2  | (55)       |
| Tualang honey                              | Oral squamous carcinomas and osteosarcoma cells           | 1–20 % for 3–48 h   | ↑ PARP cleavage<br>↑ Early apoptosis effects  | (70)       |
|  | MDA-MB-231 and MCF-7 breast cancer cells                  | 1–10 % for 6–72 h   | ↓ Mitochondrial membrane potential  | (71)       |
|  | HeLa cervical cancer cells                                |   | ↑ Caspase-3/7, -9   | (72)       |
|  | K562 and MV4-11 acute and chronic myeloid leukaemia cells | 0.1–1.0 % (v/v) for 12–48 h                                     | ↑ Apoptosis properties  | (72)       |
| Tualang honey + tamoxifen                  | MDA-MB-231 and MCF-7 breast cancer cells                  | 1 % for 6–72 h  | ↑ Caspase-3/7, -8, -9<br>↑ Mitochondrial membrane depolarisation  | (73)       |
| Gelam honey + ginger extract               | HT-29 colon cancer cells                                  | 40–80 mg/ml (honey) + 2.5–7.5 mg/ml (ginger) for 24 h           | ↑ Caspase-9, IκBα<br>↓ Bcl-XL   | (63)       |
|  | HT-29 colon cancer cells                                  | 12.5–400 mg/ml (honey) + 0.0625–4.0 mg/ml (ginger) for 24 h     | ↑ Caspase-3, Cyto C   | (64)       |
| Indian honey                               | HCT-15 and HT-29 colon cancer cells                       | 1–20 % for 12–48 h  | Arrest cell cycle at sub-G1 phase<br>↓ Non-protein thiols, mitochondrial membrane potential<br>↑ ROS, p53, caspase-3, PARP cleavage, Bax<br>↓ Bcl-2 | (74)       |
|  | MCF-7 breast cancer cells                                 | 1–20 % for 24–48 h  | Arrest cell cycle at sub-G1 phase   | (39)       |
| Polyfloral, rosemary and heather honey     | HL-60 leukaemia cells                                     | 1–125 mg/ml for 24–72 h according to different assays           | ↓ Cell viability  | (75)       |
| Monoterpene extract from Greek thyme honey | PC-3 prostate cancer cells                                | 10 <sup>-7</sup> –10 <sup>-4</sup> M for 24 h                   | ↑ Apoptosis<br>↓ NF-κB, IL-6  | (76)       |
| Egyptian honey                             | HepG2 hepatic cancer cells                                | 5–20 % for 6–72 h   | ↑ Caspase-3   | (77)       |
| Crude honey                                | HepG2 hepatic cancer cells                                | 100 µg/ml with adiponectin hormone for 24 h                     | ↓ Bcl-2<br>↓ Alkaline phosphatase activity  | (78)       |
| Modulation of oxidative stress             |   |   |   |            |
| Bees honey                                 | HepG2 hepatic cancer cells                                | 5–20 % for 6–72 h   | ↓ Cell viability<br>↑ Antioxidant enzyme<br>↓ NO  | (77)       |
| Polyfloral, rosemary and heather honey     | HepG2 hepatic cancer cells                                | 0.1–100 mg/ml for 24 h  | ↓ DNA damage  | (79)       |



**Table 2.** *Continued*

| Honeys                            | Model (cell lines or animal)             | Duration and dose/intervention                                  | Effects on cancer  | References |
|-----------------------------------|--|---|--|------------|
| Manuka honey; manuka honey + 5-FU | HCT-116 and LoVo colon cancer cells      | 10–20 and 30–40 mg/ml for 48 h<br>5–15 and 20–30 mg/ml for 48 h | ↓ Cell viability<br>↑ ROS generation<br>↓ Antioxidant enzyme activity<br>↓ Nrf2, SOD, catalase, HO-1<br>↑ Lipid peroxidation and protein carbonyl content                          | (59,80)    |
| Strawberry tree honey             | HCT-116 and LoVo colon cancer cells      | 3–12 and 10–40 mg/ml for 48 h                                   | ↑ Synergistic effects<br>↓ Cell viability<br>↑ ROS generation<br>↓ Antioxidant enzyme activity<br>↓ Nrf2, SOD, catalase, HO-1<br>↑ Lipid peroxidation and protein carbonyl content | (32,81)    |
| Ulmo honey                        | Caco-2 colon cancer cells                | 0.25–8 % for 48 h   | ↑ Lactate dehydrogenase, ROS   | (44)       |
| Tualang honey                     | MCF-7 breast cancer cells                | 1 % for 24 h  | ↑ Cytotoxicity<br>↑ DNA damage   | (44)       |
| Anti-inflammatory effects         | L929 fibrosarcoma cells                  | 1–250 µg/ml for 16–20 h   | ↓ TNF-α, NO  | (76)       |
| Malaysian honey extract           | WiDr colon cancer cells                  | 20–80 µg/ml for 12–48 h   | ↓ IL-8 secretion   | (82)       |
| Monofloral honey from Taiwan      | HCT-116 and LoVo colon cancer cells      | 10–20 and 30–40 mg/ml for 48 h                                  | ↓ NF-κB, p-IκBα  | (80)       |
| Manuka honey                      | HCT-116 and LoVo colon cancer cells      | 10–20 and 30–40 mg/ml for 48 h<br>5–15 and 20–30 mg/ml for 48 h | ↓ Cell migration<br>↓ MMP-2 and MMP-9<br>↓ N-cadherin and β-catenin<br>↑ E-cadherin<br>↑ Synergistic effects   | (59,80)    |
| Anti-metastatic effects           | HCT-116 and LoVo colon cancer cells      | 10–20 and 30–40 mg/ml for 48 h<br>5–15 and 20–30 mg/ml for 48 h | ↓ Cell migration<br>↓ MMP-2 and MMP-9<br>↓ N-cadherin and β-catenin<br>↑ E-cadherin  | (59,80)    |
| Manuka honey; manuka honey + 5-FU | HCT-116 and LoVo colon cancer cells      | 10–20 and 30–40 mg/ml for 48 h<br>5–15 and 20–30 mg/ml for 48 h | ↓ Cell migration<br>↓ MMP-2 and MMP-9<br>↓ N-cadherin and β-catenin<br>↑ E-cadherin  | (59,80)    |
| Manuka honey                      | MDA-MB-231 and MCF-7 breast cancer cells | 0.25–2 % (w/v) for 24–72 h                                      | ↓ Cell migration<br>↓ Cell invasion  | (56)       |
| Strawberry tree honey             | HCT-116 and LoVo colon cancer cells      | 3–12 and 10–40 mg/ml for 48 h                                   | ↓ Cell migration<br>↓ MMP-2 and MMP-9<br>↓ N-cadherin and β-catenin<br>↑ E-cadherin  | (81)       |
| Polish honey                      | U87MG glioblastoma cells                 | 0.5–7.5 % for 24–72 h   | ↓ MMP-2 and MMP-9  | (66)       |
| Crude honey                       | HepG2 hepatic cancer cells               | 100 µg/ml for 24 h  | ↓ Protease and gelatinase activities   | (83)       |

Honey and cancer

5-FU, 5-fluorouracil; Akt, protein kinase B; CDK, cyclin-dependent kinase; HER2, human epidermal growth factor receptor 2; MCF-7, Michigan Cancer Foundation-7; MMP, matrix metalloproteinase; p-Akt, phosphorylated protein kinase B; p-IκBα, phosphorylated inhibitor of κB; p-p38MAPK, phosphorylated p38 mitogen-activated protein kinase; ROS, reactive oxygen species; SOD, superoxide dismutase.

lymphoma-2 (Bcl-2) and p53<sup>(54,57)</sup>. The authors concluded that chrysin was the main phenolic compound responsible for the anti-proliferative effect<sup>(57)</sup>. Furthermore, Astragalus honey treatment decreased the viability of human hepatic (HepG2) and bladder (5637) carcinoma cells<sup>(58)</sup>, where mRNA levels of only Bcl-2 were decreased but no significant changes were observed in p53 mRNA<sup>(58)</sup>.

The anti-proliferative effect of manuka honey was observed on a panel of cancer cells such as colon (CT-26, HCT-116 and LoVo), breast (MDA-MB-231 and MCF-7 (Michigan Cancer Foundation-7)) and melanoma (B16-F1)<sup>(30,55,56)</sup> and found to be time and dose dependent. The anti-proliferative effect was associated with cell cycle arrest at the S and G2/M phases due to alterations in cell cycle regulatory genes such as p21, p27, cyclin-dependent kinase (CDK) 2, CDK4, cyclin D1 and cyclin E. Moreover, it was reported that manuka honey suppressed the expression of oncogenic signalling pathways such as epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER2), phosphorylated protein kinase B (p-Akt) and IL-6/signal transducer and activator of transcription (IL-6/STAT3), while it increased the expression of phosphorylated p38 mitogen-activated protein kinase (p-p38MAPK) and phosphorylated extracellular signal-regulated kinase 1/2 (p-Erk1/2)<sup>(30,56)</sup>. The anti-proliferative effects of manuka honey on HCT-116 and LoVo cancer cells significantly increased after this honey was combined with 5-fluorouracil (5-FU), while the concentration of 5-FU was lower compared with a single dose<sup>(59)</sup>. Greek honey extract (thyme, pine and fir) significantly decreased the viability of breast (MCF-7), prostate (PC-3) and endometrial (Ishikawa) cancer cells<sup>(33,60)</sup> whereas thyme honey inhibited MCF-7 cell progression by suppressing oestrogenic effects<sup>(60)</sup>. Anatolian honey with varied botanical origin (chestnut, pine and cedar) induced stronger inhibitory effects on different breast cancer cells, such as MCF-7, SKBR3 and MDA-MB-231, in a time- and dose-dependent manner<sup>(61)</sup>.

In HT-29 cancer cells, gelam honey and nenas honey inhibited cell proliferation by increasing DNA damage and suppressing several inflammation markers (PGE<sub>2</sub>; PGE<sub>2</sub>) production<sup>(62)</sup>. In addition, the anti-proliferative effects of gelam honey increased when it was combined with ginger extract compared with single compounds<sup>(63,64)</sup>. This co-treatment significantly suppressed the expression of Kirsten rat sarcoma virus oncogene homolog (Kras)-Erk, phosphatidylinositol 3-kinase (PI3K)-Akt, mammalian target of rapamycin (mTOR) and wingless-type (Wnt)/ $\beta$ -catenin pathways in HT-29 colon cancer cells<sup>(63,64)</sup>. Synergistic effects were observed when this honey was combined with 5-FU via enhancement of pro-apoptotic effects on HCT-116 cancer cells compared with 5-FU alone<sup>(65)</sup>.

Finally, in glioblastoma (U87MG) cells, Polish honey decreased cell viability by reducing DNA synthesis and diastase activity, whereas polyphenol and Cd content had a significant impact on its anti-proliferative effects<sup>(66)</sup>.

In an azoxymethane-induced rat model of colon cancer, kelulut honey inhibited aberrant crypt formation while concurrently normalising liver and kidney functions and blood parameters<sup>(84)</sup>. In a murine Ehrlich ascites carcinoma model, Indian honey and its phenolic constituent (eugenol) significantly decreased

tumour growth<sup>(85)</sup>, while in leukaemia cancer they did not induce any significant changes<sup>(86)</sup>. Bee honey protected against diethylnitrosamine-induced rat hepatocarcinogenesis by reducing weight loss, tumour size and inflammatory responses<sup>(87)</sup>. These effects correlated with normalisation of the levels of proliferation markers, like proliferating cell nuclear antigen (PCNA) and p53 in liver tissue<sup>(87)</sup>.

### Induction of apoptosis

In lung (NCI-H460)<sup>(54)</sup>, prostate (PC-3)<sup>(67)</sup> and breast (MCF-7)<sup>(68)</sup> cancer cell lines, acacia honey induced apoptosis by arresting the cell cycle at the G0/G1 phase and increasing the production of immune-modulatory cytokines such as TNF- $\alpha$  and IL-1 $\beta$ , which induced Ca ion release from the endoplasmic reticulum<sup>(54,67)</sup>. Manuka and strawberry tree honey induced apoptotic death of HCT-116 and LoVo cells by increasing p53, cleaved poly (ADP-ribose) polymerase (c-PARP) and caspase-3 expression. Additionally elevated mRNA levels of both intrinsic and extrinsic apoptotic markers such as caspase-8, caspase-9, Bcl-2-associated X protein (Bax), fatty acid synthetase (Fas) ligand (FasL) and cytochrome C (Cyto C) were also observed after manuka honey treatment<sup>(30,69)</sup>. On the same cell lines, manuka honey induced synergistic effects when used with lower concentrations of a chemotherapeutic drug (5-FU)<sup>(59)</sup>. Additionally, in MDA-MB-231 cells, manuka honey increased the enzymic activity of the caspase cascade (3/7, 6, 8 and 9) which correlated with increased Bax and decreased Bcl-2 expression, while in MCF-7 cells it induced only caspase-6 and caspase-9 activation<sup>(56)</sup>. Concurrently, manuka honey treatment translocated Cyto C from mitochondria to cytosol and Bax from cytosol to mitochondria<sup>(56)</sup>. In murine melanoma B16-F1 cells, manuka honey activated the mitochondria-dependent apoptotic pathway by increasing caspase-3/7 and caspase-9 enzyme activities as well as suppressing Bcl-2 expression, increasing c-PARP and DNA fragmentation<sup>(55)</sup>. The same group of researchers also reported that intravenous administration of manuka honey reduced tumour size and increased caspase-3 in a syngeneic melanoma model, additionally improving the survival rate of paclitaxel-treated mice by inducing parallel protective effects<sup>(55)</sup>.

Flow cytometric analysis revealed that tualang honey induced early apoptosis in oral squamous carcinomas and osteosarcoma cells<sup>(70)</sup> and early and late apoptosis effects in breast (MCF-7 and MDA-MB-231) and cervical (HeLa) cancer cells<sup>(71)</sup>. Tualang honey activated the mitochondrial apoptotic pathway by increasing caspase-3/7 and caspase-9 and decreased mitochondrial membrane potential<sup>(71)</sup>. Tualang honey promoted the apoptotic activity of tamoxifen in MDA-MB-231 and MCF-7 cells by increasing caspase-3/7, caspase-8 and caspase-9 activity, and mitochondrial membrane depolarisation compared with tamoxifen alone<sup>(73)</sup>. Signs of apoptosis, such as cytoplasmic blebs followed by formation of apoptotic bodies and rounded shape of acute and chronic myeloid leukaemia (K562 and MV4-11) cells, were also observed after this honey treatment<sup>(72)</sup>.

The early apoptotic effects of gelam honey were enhanced when used in combination with ginger extract by increasing mRNA levels of caspase-3 and -9, and Cyto C, and decreasing Bcl-XL in HT-29 cells<sup>(63,64)</sup>. Treatment of pure unfractionated

Indian honey indicated apoptosis effects in HCT-15 and HT-29 colon and MCF-7 breast cancer cells by arresting the cell cycle at the sub-G1 phase<sup>(39,74)</sup> and reducing intracellular non-protein thiols, concomitantly decreasing matrix metalloproteinase (MMP) due to an increased generation of reactive oxygen species (ROS)<sup>(74)</sup>. Additionally, this honey increased p53, caspase-3, c-PARP and Bax, and decreased Bcl-2 protein expression in a time-dependent manner<sup>(74)</sup>. Three types of Spanish honey from different floral origins such as rosemary, heather and polyfloral honey, induced ROS-independent apoptotic effects in leukaemia (HL-60) cells which were strongly co-related with their polyphenol and floral origin<sup>(75)</sup>. Monoterpene extract from Greek thyme honey induced apoptotic cell death in PC-3 prostate cancer cells by suppressing NF- $\kappa$ -light-chain-enhancer of activated B cells (NF- $\kappa$ B) phosphorylation and IL-6 secretion<sup>(76)</sup>. Egyptian honey treatment significantly suppressed HepG2 cell viability by apoptotic activation with high caspase-3 levels<sup>(77)</sup>. Additionally, the HepG2 cell survival rate decreased when crude honey combined with adiponectin hormone induced apoptosis by decreasing Bcl-2 levels and reducing alkaline phosphatase activity<sup>(78)</sup>.

### Modulation of oxidative stress

Honey is a good source of natural antioxidants whose activity is mainly due to the phenolic compounds present in honey, as we discussed earlier (Table 1). Other components such as amino acids, proteins, vitamins and carotenoid derivatives present in honey can also contribute to its antioxidant activity. The botanical and geographical origin of honey as well as climate conditions contribute to the variations in the antioxidant activity of different honeys. Several studies have reported a strong correlation between the total polyphenol and flavonoid contents and the antioxidant capacity of honey<sup>(4,88)</sup>. The antioxidant activity of honey is accredited to the ability of its bioactive compounds to scavenge or reduce the formation of free radicals, along with the improvement of mitochondrial functionality and the inhibition of DNA damage and lipid peroxidation<sup>(31)</sup>.

Bee honey was shown to inhibit the growth of HepG2 cells *in vitro* by improving the antioxidant status which could prevent the development of cancer cells, and by inducing apoptotic death<sup>(77)</sup>. Moreover, rosemary, heather and heterofloral honeys protected HepG2 cells from dietary mutagen-induced DNA damage<sup>(79)</sup>. Increased ROS generation was observed in HCT-116 and LoVo cells after treatment with manuka honey and strawberry tree honey<sup>(32,80)</sup>. Additionally, these honeys initiated oxidative stress associated with cancer cell death by: (i) decreasing antioxidant enzyme activities such as glutathione peroxidase, glutathione peroxidase, glutathione reductase, superoxide dismutase (SOD) and catalase; (ii) concomitantly suppressing the expression of nuclear-related factor 2 (Nrf2), SOD, catalase and haeme oxygenase 1 (HO-1); (iii) increasing the damage of cellular biomolecules (lipid, protein and DNA); and (iv) disrupting mitochondrial respiration and glycolysis function<sup>(80,81)</sup>. Additive effects were also observed when manuka honey was combined with 5-FU<sup>(59)</sup>.

Ulmo honey is a good source of several volatile and non-volatile compounds, which induced high cytotoxicity to

Caco-2 colon cancer cells by releasing lactate dehydrogenase and increasing intracellular ROS levels in a dose-dependent way<sup>(44)</sup>. Tualang honey potentiated the cytotoxic and genotoxic effects of 4-hydroxytamoxifen in MCF-7 breast cancer cells by increasing DNA damage and cell death. However, in non-cancer cells, this honey acted against 4-hydroxytamoxifen-induced toxicity through increasing DNA repair mechanisms<sup>(73)</sup>.

### Anti-inflammatory effects

Several studies have evaluated the anti-inflammatory effects of honey in different disease models<sup>(9,48)</sup>. Although inflammation is the key step for the initiation of carcinogenesis, only a few studies have addressed the anti-inflammatory effects of honey in fibrosarcoma<sup>(76)</sup> and colon cancer cells<sup>(80,82)</sup>. Flavonoid and phenolic acid extracts from Malaysian honey induced anti-inflammatory effects in L929 fibrosarcoma cells by decreasing TNF- $\alpha$ -induced cytotoxicity, and interferon- $\gamma$  and lipopolysaccharide-induced NO levels<sup>(76)</sup>. Furthermore, in WiDr, HCT-116 and LoVo colon cancer cells, monofloral honey from Taiwan and manuka honey from New Zealand inhibited inflammation through the suppression of IL-8 activity<sup>(82)</sup>, and NF- $\kappa$ B and phosphorylated inhibitor of  $\kappa$ B ( $p$ -I $\kappa$ B $\alpha$ ) expression<sup>(80)</sup>.

### Anti-metastatic effects

Manuka and strawberry tree honey inhibited the migration and invasion ability of HCT-116 and LoVo human colon<sup>(80,81)</sup> and MDA-MB-231 and MCF-7 breast cancer<sup>(56)</sup> cells in a time- and dose-dependent manner. These effects were mainly related to the inhibition of MMP-2 and MMP-9 expression, as well as a decrease in the expression of N-cadherin and  $\beta$ -catenin, and an increase in E-cadherin expression<sup>(80,81)</sup>. Interestingly, manuka honey increased the anti-migration and anti-invasion ability of therapeutic drugs compared with single compounds<sup>(59)</sup>. Polyphenol-rich Polish honey was shown to inhibit metastasis of U87MG cells by decreasing the activity and expression of MMP-2 and MMP-9 in a dose-dependent manner<sup>(66)</sup>. Decreased protease and gelatinase activities were observed in HepG2 cells after treatment with crude honey<sup>(83)</sup>.

### Pre-clinical studies on honey in cancer

Studies of the anti-cancer activities of honey in preclinical models are limited (Fig. 4 and Table 3<sup>(55,84,85,87,89–96)</sup>).

Tualang honey inhibited the growth of 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumours in Sprague–Dawley rats. Animals treated with oral tualang honey starting the day after DMBA administration for 150 d had delayed tumour development, multiplicity, weights and volumes compared with control animals. Vascular endothelial growth factor (VEGF), a pro-angiogenic factor, was significantly lowered in honey-treated animals<sup>(90)</sup>.

Another study reported that tualang and manuka honeys were able to slow down tumour progression in carcinogen 1-methyl-1-nitrosourea (MNU)-induced breast cancer in Sprague–Dawley rats<sup>(91)</sup>. In this study, treatments were started after the animals developed a palpable tumour. The percentage

**Table 3.** Preclinical studies evaluating the effect of honey in different cancer models

| Type of honey                | <i>In vivo</i> model   | Dose and duration  | Mechanism/effects (reported effects in treated animal)   | Reference |
|------------------------------|--|--|--|-----------|
| Jungle honey                 | Lewis lung carcinoma/2 model                                     | 1 mg/d intraperitoneally for 7 d before tumour inoculation                                       | Chemotaxis<br>↑ ROS production   | (89)      |
| Tualang honey                | DMBA-induced mammary tumours                                     | 0.2–2 g/kg (oral) for up to 150 d after DMBA administration                                      | ↓ VEGF   | (90)      |
| Tualang honey ± manuka honey | MNU-induced breast cancer  | 1 g/kg (oral) daily for 120 d  | ↑ IFN-γ and IFNGR1<br>↑ Apaf-1 caspase-9 and p53<br>↓ COX-2 and TNF-α  | (91)      |
| Manuka honey ± taxol         | B16-F1 melanoma  | 50 % (w/v) manuka honey intravenously, 10 mg/kg taxol twice weekly for 3–4 weeks                 | ↑ Caspase-3<br>↑ Survival rate   | (55)      |
| Bee honey                    | Spontaneous mammary carcinoma<br>Anaplastic colon adenocarcinoma | 2 g/kg (oral), daily for 10 d<br>1 g/kg (oral), daily for 10 d                                   | ↓ Lung nodule formation  | (92)      |
| Bee honey                    | MBT-2 bladder cancer   | 6–12 % (intralesional), twice weekly; 3 weeks<br>50 % in drinking water, alternate days; 3 weeks | ↓ Tumour volume  | (93)      |
| Bee honey                    | Diethylnitrosamine-induced liver carcinogenesis                  | 2 g/d (oral) for 6 months  | ↓ PCNA<br>↓ p53 levels   | (87)      |
| Indian honey                 | Ehrlich ascites carcinoma  | 25 % (v/v) intraperitoneally for 12 d  | ↓ Tumour growth  | (85)      |
| Kelulut honey                | Azoxymethane-induced colon cancer                                | 1183 mg/kg (oral), twice daily for 8 weeks   | ↓ Aberrant crypts, aberrant crypt foci, crypt multiplicity   | (84)      |
| Honey + aloe vera            | Walker 256 carcinoma   | 670 μl/kg (oral) for 20 d  | ↓ Tumour growth, ↓ ki67-LI   | (94)      |
| Egyptian honey               | Ehrlich ascites tumour xenograft model                           | 10–1000 mg/100 g (oral), daily for 4 weeks   | ↑ Bax:Bcl-2 ratio<br>↑ Peritoneal macrophages<br>↑ T and B cell function<br>↑ Liver and kidney enzyme activities | (95)      |
| Coriander honey              | Ehrlich ascites tumour xenograft model                           | 500 mg/kg (oral) daily for 21 d  | ↑ Total lipid and protein levels<br>↑ IgM, IgG and IgA levels<br>↑ Phagocytic activity                           | (96)      |

Apaf-1, apoptotic protease activating factor-1; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma-2; COX-2, cyclo-oxygenase 2; DMBA, 7,12-dimethylbenzanthracene; IFNGR1, interferon-γ receptor 1; IFN-γ, interferon-γ; MBT-2, murine bladder cancer cell line; MNU, 1-methyl-1-nitrosourea; PCNA, proliferating cell nuclear antigen; ROS, reactive oxygen species; VEGF, vascular endothelial growth factor.

reduction in tumour growth was significant with both tualang (71 %) and manuka (57 %) honeys. The expression levels of apoptotic protease activating factor-1 (Apaf-1) and pro-apoptotic protein, caspase-9, increased in tumour specimens of honey-treated rats. Both honeys potentiated the immune system of animals, which was evident from the increased expression levels of interferon- $\gamma$  and IFNGR1. The serum levels of oestrogen and oestrogen receptor 1 were significantly reduced in treated animals compared with controls. Thus, tualang and manuka honeys administered orally exhibit anti-cancer activities by modulating the immune system and activating the intrinsic apoptotic pathway<sup>(91)</sup>. In a separate study, oral administration of kelulut honey reduced the number of azoxymethane-induced aberrant crypt foci and crypt multiplicity in Sprague–Dawley rats, indicating that it has chemopreventive properties. Honey was administered orally, twice daily for 2 weeks, after induction with azoxymethane<sup>(84)</sup>. The authors tried to mimic the traditional human dosage of honey, which they reported as twice daily, and based on density of honey the dose conversions were made. However, this study did not give much insight on the mechanism. In another study, aloe vera increased the chemopreventive effects of honey in an *in vivo* Walker carcinoma model by reducing tumour growth and Ki67-Li expression, and increasing tumour apoptosis<sup>(94)</sup>. The study administered a combination of oral honey and aloe vera solution to tumour-bearing mice, but failed to give discernment on whether the activity was synergistic or not.

Dietary supplementation with Egyptian honey and *Nigella sativa* induced higher protection against MNU-triggered oxidative damage and colon adenocarcinoma in Sprague–Dawley rats via reduction of lipid peroxidation and NO levels. Oral treatments began 1 week after MNU induction and the authors reported that honey and *N. sativa* administered together gave 100 % protection compared with 80 % protection by *N. sativa* alone<sup>(97)</sup>. Bee honey was also found to prevent liver carcinogenesis in diethylnitrosamine (DEN)-administered rats. The authors used 2 g honey per rat per d orally for 6 months starting 1 week after DEN and showed that honey had a protective effect against inflammation and DEN-induced carcinogenesis<sup>(87)</sup>. Such a concentration of honey given for a long period of time could have confounded the findings due to the carbohydrates and a control of sugar intake should have been included.

In a separate study, pre-treatment with Egyptian honey was shown to inhibit the growth of Ehrlich ascites tumours in mice by increasing cell recruitment and enhancing the function of T and B cells as well as macrophages<sup>(95)</sup>. The authors reported that this preventive peroral treatment 4 weeks before tumour inoculation also normalised liver and kidney functions in tumour-bearing mice. In a related study, coriander honey improved the immune status of Ehrlich ascites carcinoma-bearing mice by enhancing macrophage phagocytic activity and immunoglobulin levels and maintaining normal kidney and liver enzyme activities, leading to enhanced survival<sup>(96)</sup>. The precise mechanism by which honey affects the immune status in this model is unknown.

A study on the effect of various bee products in murine tumour models demonstrated a predominant anti-metastatic effect. The study was done in two transplantable, syngeneic animal models, a murine mammary carcinoma and an anaplastic

colon adenocarcinoma in rats<sup>(92)</sup>. Treatment with oral honey led to a pronounced decrease in lung metastasis in both tumour models when given daily, starting 10 d before tumour inoculation. Surprisingly, however, administration of honey after tumour implantation appeared to enhance metastasis. This suggests that honey and its polyphenolic components stimulate the host's anti-tumour defence. Furthermore, intravenous, but not intraperitoneal or subcutaneous, administration of royal jelly had a significant anti-metastatic effect. This study also reported on the anti-tumour and anti-metastatic effects of bee venom, water-soluble derivatives and related polyphenolic compounds of propolis<sup>(92)</sup>.

Jungle honey was reported to enhance anti-tumour immunity in mice injected with Lewis lung carcinoma/2 cells. Decreased tumour incidence in honey-treated mice (1 mg per mouse per d intraperitoneally starting 7 d before tumour inoculation) correlated with an increased chemotactic response by neutrophils and ROS production by activated neutrophils<sup>(89)</sup>. In another study, intraperitoneal administration of 25 % (v/v) bee honey 1 d after tumour inoculation significantly inhibited the growth of Ehrlich ascites carcinoma in mice. The anti-tumour effect of honey against Ehrlich ascites was attributed to the phenolic content and its antioxidant ability<sup>(85)</sup>. Insights into the mechanisms that underlie these effects await further, more detailed, studies.

In a therapeutic murine melanoma model, intravenous administration of manuka honey was shown to increase the survival of B16-F1 tumour-bearing mice. Animals treated with honey alone or in combination with paclitaxel, 11 d post-tumour implantation, showed a 33 and 66 % reduction in tumour growth, respectively<sup>(55)</sup>. Immunohistochemical examination of the tumours showed an increased number of caspase-3-positive cells in honey or paclitaxel-treated groups compared with control animals. The number of apoptotic cells was highest in the animals treated with manuka honey plus paclitaxel<sup>(55)</sup>. Interestingly, overall survival of animals treated with the combination of manuka honey and paclitaxel was significantly higher than animals treated with the honey or paclitaxel alone. This suggested that combining manuka honey with paclitaxel improves efficacy of the treatment while decreasing the toxic side effects of the chemotherapeutic drug<sup>(55)</sup>.

Finally, bee honey was investigated for its tumour-inhibitory effect in the MBT-2 bladder cancer model in C3H/He mice. This study reported that 6 and 12 % solutions of honey were effective in reducing the tumour volume when injected into the tumour lesions (intralesional). Moreover, a 50 % solution administered perorally was able to inhibit tumour growth<sup>(93)</sup>. However, no mechanism for this anti-tumour effect was described.

Overall, these studies corroborate the anti-cancer potential of honey in preventative and therapeutic models. However, there is a lack of well-controlled preclinical studies on its immunomodulatory and chemopreventive effects at physiologically relevant concentrations. There is also a need to standardise the honeys studied and include proper sugar controls in experiments. Another shortcoming of the previous studies is the paucity of data on the effect of combination treatment with honey and standard chemotherapeutic drugs. Despite several studies investigating the effect of oral honey, there are few promising reports available on its potential effects when administered



parenterally, an area of investigation that could be further explored. Moreover, mechanistic studies are needed to identify the cellular targets of honey and investigate its effect on specific cancer-related signalling pathways.

### A note on clinical studies on honey in cancer

Honey has been used as a complementary medicine and is believed to improve the quality of life of cancer patients. However, there is a dearth of clinical trials testing the potential utility of honey in cancer patients. One of the few areas in which good evidence has been obtained is in the capacity of orally administered honey to ameliorate radiation-induced mucositis in patients with head and neck cancer. Several recent studies conducted in different centres have confirmed that different types of honey, including manuka and thyme, can alleviate radiation-induced mucositis in patients treated for head and neck cancers<sup>(98–101)</sup>. Importantly, no effect on actual cancer growth was reported in these studies. In a meta-analysis of randomised clinical trials, it was concluded that honey can effectively reduce the severity of chemotherapy-induced mucositis<sup>(102)</sup>. In contrast, a randomised clinical trial testing the effectiveness of manuka honey on radiation-induced esophagitis reported that it was not superior to the standard supportive care<sup>(103)</sup>. In a separate double-blind randomised trial involving fifty-two subjects, cancer-related fatigue was reduced in patients who received 5 ml (twice daily for 4 weeks) of processed honey and royal jelly<sup>(104)</sup>. In another double-blind, randomised, placebo-controlled study in 107 patients receiving chemotherapy for acute myeloid leukaemia, administration of honey and *ardeh* (sesame paste) ameliorated gastrointestinal complications, neutropenia and reduced fever<sup>(94)</sup>. Moreover, a randomised cross-over clinical trial in forty children, aged 2.5–10 years, with acute lymphoblastic leukaemia reported a significant decrease in febrile neutropenia episodes and improved levels of Hb after honey (raw clover honey) consumption<sup>(97)</sup>. Overall, there is good evidence for the beneficial use of honey in reducing chemotherapy/radiotherapy-induced toxic side effects, including fatigue, mucositis, neutropenia and gastrointestinal complications. Furthermore, a recent study reported that honey could also have a direct effect on growth of breast cancer. In a randomised controlled trial on patients with hormone receptor-positive breast cancer, combining tualang honey with the aromatase inhibitor anastrozole as adjuvant endocrine therapy reduced background parenchymal enhancement, a correlate of cancer recurrence, more effectively than treatment with anastrozole alone (42 % compared with 10 % reduction, respectively)<sup>(105)</sup>. These encouraging early findings should promote further interest in conducting well-controlled trials to directly evaluate the potential utility of honey as an adjuvant treatment in different types of cancer.

### Anti-cancer effects of major phenolic/flavonoid compounds in honey

The composition of honey varies depending on the source and geographical origin. For example, the principal flavonoids in

manuka honey are pinobanksin, pinocembrin, luteolin and chrysin accounting for about 61 % of the total flavonoid content, with other flavonoids like quercetin, 8-methoxykaempferol, isorhamnetin, kaempferol and galangin found in lesser amounts<sup>(106)</sup>. In tualang honey, the major flavonoids are catechin, kaempferol, naringenin, luteolin and apigenin<sup>(107,108)</sup>. The anti-cancer effects of the major flavonoids of honey (Table 4)<sup>(109–153)</sup> will be discussed in this section.

### Pinocembrin and pinobanksin

Pinocembrin is a flavonoid present in honey and various plants of the Piperaceae, Lauraceae and Asteraceae families and reported to have various pharmacological properties including anti-bacterial, antioxidant, anti-cancer and anti-mutagenic activities<sup>(154–156)</sup>. Pinocembrin induced Bax-dependent apoptosis in HCT-116 colon cancer cells<sup>(157)</sup>. The proapoptotic activity of various polyphenols (caffeic acid, chrysin, galangin, ferulic acid, pinocembrin and *p*-coumaric acid) was studied in CAL-27 (human tongue squamous cell carcinoma) cells. Galangin was the most potent among the group with a half maximal inhibitory concentration (IC<sub>50</sub>) of 44.5 µg/ml, followed by chrysin (54.1 µg/ml), ferulic acid (99.6 µg/ml), caffeic acid (130.3 µg/ml), pinocembrin (135.2 µg/ml) and *p*-coumaric acid (139.2 µg/ml). Polyphenols were able to induce tumour apoptosis through mitochondrial and death receptor pathways<sup>(109)</sup>. Pinocembrin inhibited metastasis of retinoblastoma cells (Y-79 cells) through the inhibition of αvβ3 integrin receptor and the focal adhesion kinase (FAK)/p38α/NF-κB signalling pathway, thereby decreasing the expression of MMP-2 and MMP-9. Pinocembrin inhibited the transforming growth factor β (TGF-β1)-induced invasion and migration of Y-79 cells, increased E-cadherin, and decreased vimentin and N-cadherin levels<sup>(110)</sup>. Pinocembrin also had an anti-proliferative and apoptotic effect on androgen-sensitive (LNCaP) and androgen-independent (PC3 and DU-145) prostate cancer cell lines through the disruption of MMP and arrest of cell cycle at the S and G2/M phases<sup>(111)</sup>. Pinobanksin and its derivatives have been reported to have antioxidant activity and induce apoptosis in B-cell lymphoma cell lines through a loss of mitochondrial membrane potential and activation of caspases. In this study, *Sonoran propolis* was studied for apoptotic activity and its chemical components were identified. Eighteen flavonoids were characterised, with pinobanksin and its ester derivatives, pinocembrin and chrysin, identified as the major components. The IC<sub>50</sub> of pinobanksin was found to be 52.1 µM whereas pinocembrin did not show any anti-proliferative effects<sup>(112)</sup>.

### Chrysin

Chrysin has been reported to have efficacy against various types of cancers *in vitro* and *in vivo*. In a recent study, chrysin inhibited the growth of B16-F10 melanoma cells *in vitro* by inducing cell cycle arrest and apoptosis<sup>(113)</sup>. In addition, oral administration of chrysin to B16-F10-implanted mice was shown to decrease tumour growth significantly. This was associated with an enhanced anti-tumour activity of macrophages, natural killer cells and cytotoxic T lymphocytes<sup>(113)</sup>. However, the mechanism(s) for chrysin-induced immune system enhancements remains to be elucidated.



**Table 4.** Effect of flavonoids on different pathways in cancer

| Flavonoids  | Cell lines/animal models   | Duration and dose/intervention   | Anti-cancer effects  | References |
|-------------|--|----------------------------------|--|------------|
| Pinocembrin | CAL-27 tongue squamous carcinoma   | 50 µg/ml for 24 h                | ↑ Intrinsic apoptotic pathway; caspase-3   | (109)      |
|             | Y-79 human retinoblastoma  | 5 µM for 24 h                    | ↓ FAK/p38MAPKα/NF-κB, MMP-2 and -9<br>↓ αvβ3 integrin receptor                           | (110)      |
|             | LNCaP human prostate cancer  | 100 and 150 µM for 24 h          | Disruption of mitochondrial membrane potential<br>Arrest cell cycle at S and G2/M phases | (111)      |
| Pinobanksin | M12.C3.F6 mouse B-cell lymphoma  | 50 µM for 12 h                   | Loss of mitochondrial membrane potential, induction of apoptosis                         | (112)      |
| Chrysin     | B16-F10 mouse melanoma   | 15–60 µM for 48 h                | Cell cycle arrest, ↑ apoptosis   | (113)      |
|             | B16-F10 melanoma model <i>in vivo</i>  | 50 mg/kg for 14 and 21 d         | ↑ Activity of macrophages, natural killer cells and T lymphocytes                        | (114)      |
|             | T47D human breast cancer cells   | CH + silibinin, 20–120 µM; 48 h  | ↓ Cyclin D1 and hTERT  | (115)      |
|             | HTh7 and KAT18 human anaplastic thyroid carcinoma cells                      | 25–50 µM for 48 h                | ↑ Notch1 intracellular domain and Hes1   | (116)      |
|             | HTh7 cell xenograft model  | 75 mg/kg for 21 d                | ↑ Cleaved PARP   | (117)      |
|             | SW48, SW480, and SW620 human colorectal cancer cells                         | 50 µM for 24 h                   | ↑ ROS, ↓ Akt/mTOR pathway  | (118)      |
|             | T-24 cells human bladder cancer cells  | 20–80 µM for 24 h                | ↑ Autophagy<br>↑ ROS, ↓ p-STAT3  | (119)      |
|             | DU145 and PC-3 prostate cancer cell  | 5–100 µM for 24 h                | ↑ p-Erk, eIF2α and activating transcription factor 4                                     | (120)      |
|             | U251/U87 human glioblastoma cells  | 10–60 µM for 24 h                | ↑ ROS, p-Erk, eIF2α and GRP78  | (121)      |
|             | U87 xenograft model  | 40–80 mg/kg, five times per week | ↓ HO-1<br>↓ NAD (P)H quinine oxidoreductase-1<br>↓ Nrf2, ↓ p-Erk                         | (122)      |
| Galangin    | CAL-27 human tongue carcinoma  | 5 µg/ml for 24 h                 | ↑ PRDH/POX, ↓ collagen biosynthesis  | (123)      |
|             | MDA-MB-231, BT-549 breast cancer   | 5–20 µM for 48 h                 | ↓ MMP-9, PI3/Akt and EMT   | (124)      |
|             | B16-F10 mouse melanoma   | 50 µM for 24 h                   | ↓ FAK  | (125)      |
|             | B16-F10 tail vein metastatic model   | 50 mg/kg for 14 d                |  | (126)      |
|             | TU212 and HEP-2 laryngeal cells  | 30 µM for 24 h                   | ↓ PI3K/Akt/NF-κB   | (127)      |
|             | 786-0 and Caki-1 renal cell carcinoma  | 100 µM for 24 h                  | ↓ N-cadherin and vimentin, ↑ E-cadherin  | (128)      |
|             | HXO-Rb44 and Y-79 human retinoblastoma cells                                 | 20–80 µM for 48 h                | ↑ PTEN, ↓ Akt, ↓ Ki-67   | (129)      |
|             | HT-1080 human fibrosarcoma   | 15–30 mg/kg daily for 21 d       | ↑ Cleaved caspase-3  | (130)      |
|             | A2780/CP70, OVCAR-3 ovarian carcinoma  | 30 µM for 24 h                   | ↓ NF-κB and AP-1   | (131)      |
|             | A549 and A549/DDP lung cancer  | 10–60 µM for 24 h                | ↓ VEGF, ↓ Akt/p70S6K/HIF-1α  | (132)      |
|             | HeLa human cervical carcinoma  | 2–10 µM for 24 h                 | ↓ NF-κB, ↓ STAT3, ↑ Bax:Bcl-2 ratio  | (133)      |
|             | SGC-7901 human gastric cancer  | 25–100 µM for 24 h               | ↓ Nrf-2, ↓ glyoxalase-1, ↑ ROS   | (134)      |
|             | HepG2 human hepatocellular carcinoma   | 160 µmol/l for 48 h              | ↓ MMP; ↑ caspase-8/Bid/Bax   | (135)      |
|             | HepG2, Hep3B and PLC/PRF/5 human hepatocellular carcinoma                    | 37–148 µM for 24 h               | Autophagy induction, ↑ TGF-β receptor-regulated SMAD                                     | (136)      |
| Luteolin    | HepG2, Hep3B and PLC/PRF/5 human hepatocellular carcinoma                    | 79–134 µM for 24 h               | ↑ MAPK pathway<br>↑ Mitochondrial Ca <sup>2+</sup> uptake                                | (137)      |
|             | PC-3 prostate cancer cells   | 5 µM for 24 h                    | ↑ FZD6, ↓ Wnt/β-catenin pathway  | (138)      |
|             | U-87/U-251 MG human glioblastoma   | 10–80 µM for 48 h                | ↑ EGFR, ↓ Akt and MAPK signalling  | (139)      |
|             | HL-60 human leukaemia  | 35 µM from 0–12 h                | ↑ Histone H3 acetylation, Erk/JNK  | (140)      |
|             | HeLa cervical carcinoma, MCF-7 breast cancer, Hep3B hepatocellular carcinoma | 20–50 µM for 24 h                | Hsp90 blockade, ↓ STAT3  | (141)      |
|             | A-549 human lung cancer  | 50 µM for 24 h                   | ↓ Claudin-2, ↓ STAT3   | (142)      |
|             | SGC7901/DDP human gastric cancer   | 10 µM for 24 h                   | ↓ STAT3  | (143)      |
|             | KKU-M156 cholangiocarcinoma  | 0.3–10 µM for 2 h                | ↓ Janus kinase/STAT3   | (144)      |
|             | MDA-MB231 human breast cancer  | 20 µM from 0–4 h                 | ↓ MMP1 and CYP1A1 activity   | (145)      |
|             | PANC-1 and SW1990 pancreatic cancer  | 20–160 µM for 24 h               | ↓ STAT3, ↑ Fas, ↑ caspase-3, -8<br>↓ STAT3, ↓ MMP-2, -7, -9                              | (146)      |
|             | Hep3B hepatocellular carcinoma   | 10 µM for 48–72 h                | ↓ CDH2, vimentin, ZEB1 and Snail<br>↑ JNK  | (147)      |

Honey and cancer



expression level of FAK, a regulator of cancer cell invasion and metastasis. Galangin also reduced the metastatic lung nodules of B16-F10 melanoma cells and immunohistochemical studies showed reduced FAK expression in lung tissues<sup>(122)</sup>.

Proliferation, invasion and metastasis of human laryngeal cells (TU212 and HEP-2) were prevented by galangin through suppression of the PI3K/Akt/NF- $\kappa$ B pathway. Galangin induced apoptosis and regulated autophagy in both cell lines. In the TU212 xenograft mouse model, galangin decreased the tumour volume with reduction of Ki-67 expression and increased number of TUNEL positive cells<sup>(123)</sup>. It has also been reported that galangin inhibits the cell cycle and induces apoptosis in human breast cancer (MCF-7) and human nasopharyngeal carcinoma (NPC-TW076 and NPC-TW039) by inhibiting the PI3K-Akt signalling pathway<sup>(161,162)</sup>. Galangin suppressed the proliferation of retinoblastoma cells (HXO-Rb44 and Y-79) both *in vitro* and *in vivo* reportedly through reduction in Akt activity, induction of apoptosis and the increased expression of the phosphatase and tensin homolog (PTEN) tumour suppressor gene<sup>(125)</sup>. In a separate study, galangin suppressed epithelial-mesenchymal transition (EMT) and proliferation of 786-0 and Caki-1 renal cell carcinoma. The expression of N-cadherin and vimentin decreased while there was an increased expression of E-cadherin, indicative of EMT suppression<sup>(124)</sup>.

MMP-9 is an enzyme involved in tumour development that allows cancer cells to degrade type IV collagen present in the basement membrane, thereby favouring invasion and metastasis. The flavonoids galangin and kaempferol individually suppressed phorbol 12-myristate 13-acetate-induced MMP-9 transactivation in HT-1080 (human fibrosarcoma) cells by inhibiting NF- $\kappa$ B and activator protein 1 (AP-1) pathways<sup>(126)</sup>.

In ovarian cancer cells (A2780/CP70 and OVCAR-3), VEGF, the key mediator in angiogenesis, was inhibited by galangin and myricetin in a dose-dependent manner. Additionally, expression of the Akt/p70S6K/hypoxia-inducible factor-1 $\alpha$  (HIF-1 $\alpha$ ) pathway was also inhibited after the above treatments. HIF-1 $\alpha$  directly increases the expression of VEGF. The ribosomal protein S6 kinase which is a downstream mediator of the PI3K/Akt pathway further regulates angiogenesis by modulating HIF-1 $\alpha$  and VEGF proteins. In chicken chorioallantoic membrane assay, galangin and myricetin significantly reduced the formation of blood vessels induced by OVCAR-3 cells<sup>(127)</sup>. There is also evidence that the combination of galangin and cisplatin induced apoptosis in cisplatin-resistant A549 lung cancer cells (A549/DDP). The synergistic combination acted through multiple targets like STAT3/NF- $\kappa$ B and Bax/Bcl-2 pathways and was effective in reducing tumour growth *in vivo*. Galangin and cisplatin synergistically suppressed nuclear expression of pSTAT3 and p65 and increased the Bax:Bcl-2 ratio. These results were supported by *in vivo* studies in the A549/DDP xenograft model where the combined treatment was shown to be more efficient than treatment with either compound alone<sup>(128)</sup>.

The glyoxalase system protects cells from dicarbonyl stress by converting the toxic methylglyoxal (MG) to D-lactate. Galangin modulated Nrf-2 levels in HeLa cells resulting in decreased glyoxalase-1 levels and thereby leading to decreased MG detoxification. Increased accumulation of MG resulted in

oxidative stress-induced cell death<sup>(129)</sup>. Manuka honey contains elevated levels of MG which contribute to its anti-bacterial properties<sup>(163)</sup>. Recently MG has been studied for its role in cancer, and multiple mechanisms have been reported. MG is an endogenously produced metabolite and a potent glycating agent of cell components resulting in production of advanced glycation endproducts. MG can induce apoptosis through ROS generation, accumulation of advanced glycation endproducts or oxidative DNA damage<sup>(164)</sup>. MG induced apoptosis in human osteoblasts and Jurkat leukaemia T cells through oxidative stress, c-Jun N-terminal kinase (JNK) activation, loss of MMP, Cyt c and activation of caspases<sup>(165,166)</sup>. MG also inhibited mitochondrial complex I in sarcoma 180 cells resulting in mitochondrial membrane potential loss and release of Cyt c, which ultimately led to apoptosis<sup>(167)</sup>. Moreover, MG was found to disturb the defence mechanisms of MCF-7 cells to oxidative stress and activated caspase-3. The expression of Ki-67 (cell proliferation marker) was lowered, which was indicative of the anti-proliferative effect of MG<sup>(164)</sup>. These studies stipulate that in addition to its anti-bacterial effects, MG also contributes to the anti-cancer potential of manuka honey.

In a human gastric cancer cell line (SGC-7901), treatment with galangin and quercetin increased the number of apoptotic cells compared with control. Galangin was more potent than quercetin in decreasing mitochondrial membrane potential, leading to apoptosis through a mitochondrial pathway involving caspase-8/Bid/Bax activation<sup>(130)</sup>. Further, in HepG2 hepatocellular carcinoma, galangin treatment activated TGF- $\beta$ R and receptor-regulated SMAD and suppressed the inhibitor SMAD, resulting in increased TGF- $\beta$ R/SMAD signalling and induction of autophagy and apoptosis in a dose-dependent manner<sup>(131)</sup>. Another study reported that apoptosis induction by galangin in hepatocellular carcinoma cells was due to prolonged endoplasmic reticulum stress via activation of MAPK pathways (p38 MAPK, JNK and Erk subfamilies). These MAPK are positive regulators of endoplasmic reticulum stress-induced apoptosis. Galangin also increased cytosolic free Ca<sup>2+</sup> and mitochondrial Ca<sup>2+</sup> uptake leading to mitochondria-mediated cell death<sup>(132)</sup>.

### Luteolin

Luteolin (3,4,5,7-tetrahydroxy flavone) is a heat-stable flavonoid with anti-cancer, anti-oxidant and anti-inflammatory properties<sup>(168)</sup>. In prostate cancer, luteolin inhibited cell growth through the regulation of the Wnt/ $\beta$ -catenin pathway. Luteolin inhibited the migration of PC-3 cells in transwell and wound healing assays. Moreover, it decreased spheroid formation and self-renewal (or stemness) of these cells by up-regulating frizzled class receptor 6, a negative regulator of the Wnt pathway, that plays an important role in tumorigenesis<sup>(133)</sup>. Another study using U-87 MG and U-251 MG glioblastoma cells demonstrated that luteolin inhibited epidermal growth factor receptor (EGFR) and its downstream Akt and MAPK signalling pathways. Luteolin reduced Bcl-xL and increased the levels of cleaved caspase-3, indicating apoptosis. DNA repair pro-survival mechanism was inhibited by luteolin treatment, which was indicated by increased c-PARP levels<sup>(134)</sup>. In HL-60 leukaemia cells, luteolin triggered apoptosis through Fas/FasL-mediated extrinsic pathway that was mediated

by increasing acetylation of histone H3 and activation of Erk and JNK pathways. Luteolin treatment activated caspase-3 and -8, and enhanced c-Jun activation which was correlated with FasL expression<sup>(135)</sup>.

Numerous studies have reported that luteolin's ability to inhibit STAT3 is responsible for its apoptotic and anti-metastatic activities. Luteolin blocked Hsp90, which is a stabiliser of p-STAT3 and enhanced the degradation of both Tyr705- and Ser727-phosphorylated STAT3 resulting in apoptosis of various cancer cell types<sup>(136)</sup>. In A-549 lung cancer cells, luteolin and kaempferol directly blocked STAT3–DNA interaction by inhibiting STAT3 communication with the promoter region of claudin-2, a membrane protein present at cell tight junctions<sup>(137)</sup>. Another study reported that in PANC-1 and SW1990 pancreatic cells, luteolin inhibited STAT3 and EMT in a dose-dependent manner. Luteolin treatment also inhibited the metalloproteinases MMP-2, MMP-7 and MMP-9 and reversed IL-6-induced EMT in these cells, which was partly attributed to STAT3 inhibition<sup>(142)</sup>.

STAT3 inhibition by luteolin has also been reported in gastric cancer cells. The drug-resistant cell lines (SGC7901/DDP, BGC823 and HGC27) showed higher sensitivity to luteolin when compared with the drug-sensitive cell line SGC7901. In SGC7901/DDP cells, luteolin treatment disrupted the interaction of HSP-90 and STAT-3 by increasing the binding of SHP-1 to STAT3, which ultimately promoted STAT-3 dephosphorylation. Inhibition of STAT3 was also observed in xenograft models where tumour growth significantly decreased after luteolin treatment in SGC7901/DDP and HGC27-bearing mice but not in those implanted with SGC7901 cells<sup>(118)</sup>. Similarly, luteolin inhibited Janus kinase/STAT3 activation and decreased viability of human cholangiocarcinoma (KKU-M156) cells. Luteolin significantly reduced IL-6-mediated migration of these cells<sup>(139)</sup>.

In a recent study, luteolin and apigenin were shown to suppress MMP-1 and CYP1A1 activity, which are the triggering factors of intravasation, in MDA-MB231 cells, thus preventing the movement of cell spheroids through the lymph–endothelial barrier. MMP-1 inhibition prevented the activation of FAK, a protein that facilitates cancer cell migration by loosening the cell matrix. The synergistic inhibition of CYP1A1 by apigenin and luteolin leads to decreased expression of 12(S)-HETE, a pro-intravasation metabolite that helps tumour cells to cross the endothelial barrier through the formation of circular chemorepellent-induced defects in the lymph endothelial cells<sup>(140)</sup>.

The effect of treatment with a combination of luteolin and conventional anti-cancer drugs has been reported. Enhanced apoptosis of MDA-MB-231 cells was observed with co-treatment of luteolin and paclitaxel compared with paclitaxel alone. The blocking of STAT3 resulted in the activation of Fas and caspases-3 and -8. In an *in vivo* orthotopic breast tumour model in nude mice, administration of luteolin or paclitaxel alone or in combination reduced the tumour volume by 62.3, 81.8 and 96.5 %, respectively<sup>(121)</sup>. A synergistic pro-apoptotic effect was observed when luteolin was used in combination with sorafenib, a small-molecule multi-kinase inhibitor, in hepatocellular carcinoma cells<sup>(143)</sup>.

## Quercetin

Quercetin is a ubiquitous flavonoid and its anti-cancer properties have been widely reported. A recent study reported that quercetin sensitised human ovarian cancer cells towards X-irradiation and aggravated DNA damage with significant reduction of tumour growth *in vivo*<sup>(144)</sup>. In OV2008 and A2780 cells, quercetin induced the endoplasmic reticulum stress marker CHOP (CCAAT/enhancer-binding protein homologous protein) through the PERK/ATF4/eIF2 $\alpha$  pathway which in turn promotes apoptosis by increasing the Bax:Bcl-2 ratio. Quercetin enhanced the sensitivity of cells to irradiation leading to increased DNA damage and apoptosis. Quercetin increases H2AX phosphorylation and decreases expression of Rad51, indicative of DNA damage. In an OV2008 xenograft mouse model, only the administration of quercetin 1 h before radiation significantly reduced tumour volume, compared with the individual treatments<sup>(144)</sup>.

Quercetin treatment arrested HL-60 leukaemia cells at the G1 phase and reduced tumour growth in xenograft models. In addition to induction of apoptosis, the autophagic progression of cells was also activated. Quercetin was able to stimulate autophagy of the HL-60 cells by increasing BECLIN-1, PI3K, ATG5-ATG12, ATG7 and also converting LC3-I to LC3-II, which is a distinct feature of autophagy<sup>(145)</sup>. Moreover, quercetin inhibited the growth of prostate cancer cells by modulating MAPK, Akt and ROS production<sup>(169)</sup>. In pancreatic cancer, quercetin inhibited invasion, metastasis and EMT via a blockade of the STAT3 pathway. This was mediated through a reduction in the levels of E-cadherin and increased levels of N-cadherin, vimentin, Zeb1, Twist, Slug and Snail, and the MMP-2 and MMP-7 enzymes<sup>(149)</sup>. Other studies showed that quercetin interacted with multiple pathways and induced apoptosis and autophagy in primary effusion lymphoma cells. Quercetin dephosphorylated GSK-3 leading to down-regulation of Wnt/ $\beta$ -catenin and PI3K/Akt/mTOR signalling. Quercetin also inhibited the activation of STAT3<sup>(146)</sup>. Mitochondria-mediated apoptosis of lung cancer cells was induced by quercetin through the down-regulation of the IL-6/STAT3 pathway by modulation of NF- $\kappa$ B activation. Quercetin had a time-dependent effect on apoptosis, with a significant up-regulation of caspase-3 and PARP, and down-regulation of the Bcl-2:Bax ratio<sup>(147)</sup>.

Quercetin enhanced the efficacy of conventional chemotherapeutic drugs in multi-drug-resistant BEL/5-FU (human hepatocellular carcinoma) cells over-expressing ABC transporters. Quercetin dose-dependently decreased mRNA expression of multiple transporters by blocking the FZD7/ $\beta$ -catenin pathway<sup>(148)</sup>. In breast cancer cells, quercetin down-regulated the drug-efflux ABC transporters, increased intracellular doxorubicin levels and potentiated its effect. Moreover, quercetin had a synergistic effect with doxorubicin in inducing apoptosis in MCF-7 and MDA-MB-231 cells. It has also been reported that the combination effectively eliminated stem cells in both cell lines, compared with doxorubicin treatment alone<sup>(170)</sup>.

Quercetin has also been reported to inhibit proteasomal system via suppression of the MEK1/Erk1/2 pathway, in HepG2 cells. Quercetin attenuated the  $\beta$ -subunits of proteasome

including  $\beta 5$ , which is responsible for its chymotrypsin-like activity<sup>(150)</sup>. Furthermore, quercetin inhibited EMT induced by TGF- $\beta 1$  in SW480 (human colorectal adenocarcinoma) cells via increased expression of E-cadherin and decreased expression of vimentin and Twist1, which are well-known markers of EMT and metastasis<sup>(152)</sup>.

In breast cancer cells, quercetin inhibited mammosphere formation, decreased number of foci and migration of CD44<sup>+</sup>/CD24<sup>-</sup> cancer stem cells (CSC)<sup>(153,171)</sup>. In MCF-7 cells, quercetin decreased proliferation and induced apoptosis and G1 arrest of the cell cycle by decreasing the levels of oestrogen receptor- $\alpha$ , cyclin D1 and Bcl-2, and enhancing Bax expression<sup>(171)</sup>. The inactivation of CSC was through inhibition of the PI3K/Akt/mTOR-signalling pathway<sup>(171)</sup>. Using MDA-MB-231 breast CSC, quercetin was shown to lower the expression levels of aldehyde dehydrogenase 1A1, chemokine receptor type 4, mucin 1, and epithelial cell adhesion molecules resulting in suppressed cell proliferation and invasiveness. Quercetin also arrested the G2/M phase of the cell cycle in MDA-MB-231 cells and further induced their apoptosis<sup>(153)</sup>.

It is quite intriguing that individual flavonoids exhibited anti-cancer activities at much higher concentrations than are normally present in honey. This might suggest that the anti-cancer properties of honey may be due to their synergistic or additive effects.

### Concluding remarks

It is evident from the available reports that honey is an immune modulator and possesses anti-proliferative, apoptotic and anti-metastatic effects against various types of cancer. The anti-inflammatory and free radical-scavenging properties of honey also contribute to its chemopreventive effects. The chemical composition of honey is well studied and reported. Phenolic compounds, which are well-known secondary plant metabolites, are enriched in some types of honey. Until now, only two studies have addressed the bioavailability and metabolites of honey<sup>(52,53)</sup>. Significant findings from these studies strongly encourage carrying out further research work on the bioavailability properties of honey in the future. Flavonoids are an important class of phenolic compounds exhibiting a wide variety of anti-cancer, antioxidant and anti-inflammatory activities. Numerous published reports have attributed the biological/physiological properties of honey to its phenolic components. Many of the studied flavonoids and other phenolic compounds showed synergistic or additive effects with standard anti-cancer drug regimens. It is quite apparent that the major flavonoids of honey, reviewed in the present paper, may act through many common pathways in different cancer cells. The ability of natural compounds to ubiquitously act on multiple pathways could be the reason for their various modes of action and greater safety profiles. However, one of the potentially important factors that has not been addressed in the majority of previous studies is the effect of sugars on the models tested.

Carcinogenesis is a multi-step process with initiation, promotion and progression stages. There is evidence that honey is able to successfully combat the different stages of cancer development. Researchers are exploring the effect of honey on various signalling pathways to uncover the mechanisms by which it acts

against cancer. One of the major tasks would be to define the precise upstream molecular targets by which honey affects cancer growth. In preclinical studies, honey has been shown to be safe with no detectable side effects. Honey also has the ability to mitigate the toxicity of standard chemotherapeutic drugs, most probably through its antioxidant properties. Additional preclinical studies using different models of cancer on honey are needed to verify and extend the promising *in vitro* data before moving on to clinical trials.

### Acknowledgements

Work in Professor Basel al-Ramadi's laboratory was supported by a Zayed Centre grant (no. 31R025) from the Office of Research and Sponsored Projects, UAE University.

S. A. and S. M. H. researched the data and prepared the first draft of the manuscript. M. J. F.-C. and F. G. supervised the writing and edited the manuscript. B. K. a.-R. and M. B. designed and planned the manuscript, and revised and edited the final version for submission. All authors approved the manuscript.

The authors have no relevant interests to declare.

### References

1. Castro-Vázquez L, Díaz-Maroto MC & Pérez-Coello MS (2006) Volatile composition and contribution to the aroma of Spanish honeydew honeys. Identification of a new chemical marker. *J Agric Food Chem* **54**, 4809–4813.
2. Manyi-Loh CE, Ndip RN & Clarke AM (2011) Volatile compounds in honey: a review on their involvement in aroma, botanical origin determination and potential biomedical activities. *Int J Mol Sci* **12**, 9514–9532.
3. Martinotti S & Ranzato E (2018) Honey, wound repair and regenerative medicine. *J Funct Biomat* **9**, E34.
4. Alvarez-Suarez JM, Tulipani S, Díaz D, *et al.* (2010) Antioxidant and antimicrobial capacity of several monofloral Cuban honeys and their correlation with color, polyphenol content and other chemical compounds. *Food Chem Toxicol* **48**, 2490–2499.
5. Afrin S, Gasparrini M, Forbes-Hernández TY, *et al.* (2018) Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 1: Enhancement of cellular viability, regulation of cellular apoptosis and improvement of mitochondrial functionality. *Food Chem Toxicol* **121**, 203–213.
6. Gasparrini M, Afrin S, Forbes-Hernández TY, *et al.* (2018) Protective effects of manuka honey on LPS-treated RAW 264.7 macrophages. Part 2: Control of oxidative stress induced damage, increase of antioxidant enzyme activities and attenuation of inflammation. *Food Chem Toxicol* **120**, 578–587.
7. Alvarez-Suarez JM, Giampieri F & Battino M (2013) Honey as a source of dietary antioxidants: structures, bioavailability and evidence of protective effects against human chronic diseases. *Curr Med Chem* **20**, 621–638.
8. Almasaudi SB, El-Shitany NA, Abbas AT, *et al.* (2016) Antioxidant, anti-inflammatory, and antiulcer potential of manuka honey against gastric ulcer in rats. *Oxid Med Cell Longev* **2016**, 3643824.
9. Badolato M, Carullo G, Cione E, *et al.* (2017) From the hive: honey, a novel weapon against cancer. *Eur J Med Chem* **142**, 290–299.
10. Miguel MG, Antunes MD & Faleiro ML (2017) Honey as a complementary medicine. *Integr Med Insights* **12**, 1178633717702869.

11. Byeongsang OH, Butow P, Mullan B, *et al.* (2010) The use and perceived benefits resulting from the use of complementary and alternative medicine by cancer patients in Australia. *Asia Pac J Clin Oncol* **6**, 342–349.
12. Erejuwa OO, Sulaiman SA, Wahab MSA (2014) Effects of honey and its mechanisms of action on the development and progression of cancer. *Molecules* **19**, 2497–2522.
13. da Silva PM, Gauche C, Gonzaga LV, *et al.* (2016) Honey: chemical composition, stability and authenticity. *Food Chem* **196**, 309–323.
14. Battino M, Forbes-Hernández TY, Gasparrini M, *et al.* (2018) Relevance of functional foods in the Mediterranean diet: the role of olive oil, berries and honey in the prevention of cancer and cardiovascular diseases. *Crit Rev Food Sci Nutr* **59**, 893–920.
15. United States Department of Agriculture (2015) Full Report (All Nutrients): 19296, Honey. National Nutrient Database, Agricultural Research Service, Release 28. <https://ndb.nal.usda.gov/ndb/foods/show/6287> (accessed October 2015).
16. Alvarez-Suarez JM, Tulipani S, Romandini S, *et al.* (2010) Contribution of honey in nutrition and human health: a review. *Med J Nutr Metab* **3**, 15–23.
17. Kamal MA & Klein P (2011) Determination of sugars in honey by liquid chromatography. *Saudi J Biol Sci* **18**, 17–21.
18. Soldatkin OO, Peshkova VM, Saiapina OY, *et al.* (2013) Development of conductometric biosensor array for simultaneous determination of maltose, lactose, sucrose and glucose. *Talanta* **115**, 200–207.
19. Escuredo O, Dobre I, Fernández-González M, *et al.* (2014) Contribution of botanical origin and sugar composition of honeys on the crystallization phenomenon. *Food Chem* **149**, 84–90.
20. Won S-R, Lee D-C, Ko SH, *et al.* (2008) Honey major protein characterization and its application to adulteration detection. *Food Res Int* **41**, 952–956.
21. Truzzi C, Annibaldi A, Illuminati S, *et al.* (2014) Determination of proline in honey: comparison between official methods, optimization and validation of the analytical methodology. *Food Chem* **150**, 477–481.
22. Iglesias MT, De Lorenzo C, Del Carmen Polo M, *et al.* (2004) Usefulness of amino acid composition to discriminate between honeydew and floral honeys. Application to honeys from a small geographic area. *J Agric Food Chem* **52**, 84–89.
23. Manzanares AB, García ZH, Galdón BR, *et al.* (2014) Physicochemical characteristics of minor monofloral honeys from Tenerife, Spain. *LWT Food Sci Technol* **55**, 572–578.
24. Hermosín I, Chicón RM & Cabezudo MD (2003) Free amino acid composition and botanical origin of honey. *Food Chem* **83**, 263–268.
25. Bogdanov S, Jurendic T, Sieber R, *et al.* (2008) Honey for nutrition and health: a review. *J Am Coll Nutr* **27**, 677–689.
26. Castro-Vázquez L, Díaz-Maroto MC & Pérez-Coello MS (2007) Aroma composition and new chemical markers of Spanish citrus honeys. *Food Chem* **103**, 601–606.
27. Moniruzzaman M, Amrah Sulaiman S & Gan SH (2017) Phenolic acid and flavonoid composition of Malaysian honeys. *J Food Biochem* **41**, e12282.
28. Chua LS, Rahaman NLA, Adnan NA, *et al.* (2013) Antioxidant activity of three honey samples in relation with their biochemical components. *J Anal Methods Chem* **2013**, 313798.
29. Küçük M, Kolaylı S, Karaoğlu Ş, *et al.* (2007) Biological activities and chemical composition of three honeys of different types from Anatolia. *Food Chem* **100**, 526–534.
30. Afrin S, Giampieri F, Gasparrini M, *et al.* (2018) The inhibitory effect of manuka honey on human colon cancer HCT-116 and LoVo cell growth. Part 1: The suppression of cell proliferation, promotion of apoptosis and arrest of the cell cycle. *Food Funct* **9**, 2145–2157.
31. Alvarez-Suarez JM, Giampieri F, Cordero M, *et al.* (2016) Activation of AMPK/Nrf2 signalling by manuka honey protects human dermal fibroblasts against oxidative damage by improving antioxidant response and mitochondrial function promoting wound healing. *J Funct Foods* **25**, 38–49.
32. Afrin S, Forbes-Hernandez TY, Gasparrini M, *et al.* (2017) Strawberry-tree honey induces growth inhibition of human colon cancer cells and increases ROS generation: a comparison with manuka honey. *Int J Mol Sci* **18**, E613.
33. Spilioti E, Jaakkola M, Tolonen T, *et al.* (2014) Phenolic acid composition, antiatherogenic and anticancer potential of honeys derived from various regions in Greece. *PLOS ONE* **9**, e94860.
34. Nousias P, Karabagias IK & Riganakos KA (2018) Deep inside polyphenols of Hellenic thyme honey. *Austin J Nutri Food Sci* **6**, 1098.
35. Kıvrak Ş & Kıvrak İ (2017) Assessment of phenolic profile of Turkish honeys. *Int J Food Prop* **20**, 864–876.
36. Hussein SZ, Yusoff KM, Makpol S, *et al.* (2011) Antioxidant capacities and total phenolic contents increase with  $\gamma$  irradiation in two types of Malaysian honey. *Molecules* **16**, 6378–6395.
37. Socha R, Juszczyk L, Pietrzyk S, *et al.* (2011) Phenolic profile and antioxidant properties of Polish honeys. *Int J Food Sci Technol* **46**, 528–534.
38. Ranneh Y, Ali F, Zarei M, *et al.* (2018) Malaysian stingless bee and tualang honeys: a comparative characterization of total antioxidant capacity and phenolic profile using liquid chromatography-mass spectrometry. *LWT Food Sci Technol* **89**, 1–9.
39. Jaganathan SK, Mandal SM, Jana SK, *et al.* (2010) Studies on the phenolic profiling, anti-oxidant and cytotoxic activity of Indian honey: *in vitro* evaluation. *Nat Prod Res* **24**, 1295–1306.
40. Moise A, Mărghitaş Liviu A, Dezmirean D, *et al.* (2013) Nutraceutical properties of Romanian heather honey. *Nutr Food Sci* **43**, 218–227.
41. Boussaid A, Chouaibi M, Rezig L, *et al.* (2014) Physicochemical and bioactive properties of six honey samples from various floral origins from Tunisia. *Arab J Chem* **11**, 265–274.
42. Hossen MS, Ali MY, Jahurul MHA, *et al.* (2017) Beneficial roles of honey polyphenols against some human degenerative diseases: a review. *Pharmacol Rep* **69**, 1194–1205.
43. Petretto GL, Cossu M & Alamanni MC (2015) Phenolic content, antioxidant and physico-chemical properties of Sardinian monofloral honeys. *Int J Food Sci Technol* **50**, 482–491.
44. Acevedo F, Torres P, Oomah BD, *et al.* (2017) Volatile and non-volatile/semi-volatile compounds and *in vitro* bioactive properties of Chilean ulmo (*Eucryphia cordifolia* Cav.) honey. *Food Res Int* **94**, 20–28.
45. Hegazi AG & Abd El-Hady FK (2007) Influence of honey on the suppression of human low density lipoprotein (LDL) peroxidation (*in vitro*). *Evid Based Complement Alternat Med* **6**, 113–121.
46. Buba F, Gidado A & Shugaba A (2013) Analysis of biochemical composition of honey samples from North-East Nigeria. *Biochem Anal Biochem* **2**, 3.
47. Nweze JA, Okafor JI, Nweze EI, *et al.* (2017) Evaluation of physicochemical and antioxidant properties of two stingless bee honeys: a comparison with *Apis mellifera* honey from Nsukka, Nigeria. *BMC Res Notes* **10**, 566.
48. Porcza LM, Simms C & Chopra M (2016) Honey and cancer: current status and future directions. *Diseases* **4**, E30.

49. Ciulu M, Spano N, Pilo MI, *et al.* (2016) Recent advances in the analysis of phenolic compounds in unifloral honeys. *Molecules* **21**, 451.
50. Manach C, Williamson G, Morand C, *et al.* (2005) Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr* **81**, 230S–242S.
51. Manach C, Scalbert A, Morand C, *et al.* (2004) Polyphenols: food sources and bioavailability. *Am J Clin Nutr* **79**, 727–747.
52. Schramm DD, Karim M, Schrader HR, *et al.* (2003) Honey with high levels of antioxidants can provide protection to healthy human subjects. *J Agric Food Chem* **51**, 1732–1735.
53. Seraglio SKT, Vales AC, Daguier H, *et al.* (2017) Effect of *in vitro* gastrointestinal digestion on the bioaccessibility of phenolic compounds, minerals, and antioxidant capacity of *Mimosa scabrella* Benth honeydew honeys. *Food Res Int* **99**, 670–678.
54. Aliyu M, Odunola OA, Farooq AD, *et al.* (2013) Molecular mechanism of antiproliferation potential of acacia honey on NCI-H460 cell line. *Nutr Cancer* **65**, 296–304.
55. Fernandez-Cabezudo MJ, El-Kharrag R, Torab F, *et al.* (2013) Intravenous administration of manuka honey inhibits tumor growth and improves host survival when used in combination with chemotherapy in a melanoma mouse model. *PLOS ONE* **8**, e55993.
56. Aryappalli P, Al-Qubaisi SS, Attoub S, *et al.* (2017) The IL-6/STAT3 signaling pathway is an early target of manuka honey-induced suppression of human breast cancer cells. *Front Oncol* **7**, 167.
57. Pichichero E, Cicconi R, Mattei M, *et al.* (2010) Acacia honey and chrysin reduce proliferation of melanoma cells through alterations in cell cycle progression. *Int J Oncol* **37**, 973–981.
58. Sadeghi-Aliabadi H, Hamzeh J & Mirian M (2015) Investigation of Astragalus honey and propolis extract's cytotoxic effect on two human cancer cell lines and their oncogen and proapoptotic gene expression profiles. *Adv Biomed Res* **4**, 42.
59. Afrin S, Giampieri F, Forbes-Hernandez TY, *et al.* (2018) Manuka honey synergistically enhances the chemopreventive effect of 5-fluorouracil on human colon cancer cells by inducing oxidative stress and apoptosis, altering metabolic phenotypes and suppressing metastasis ability. *Free Radic Biol Med* **126**, 41–54.
60. Tsiapara AV, Jaakkola M, Chinou I, *et al.* (2009) Bioactivity of Greek honey extracts on breast cancer (MCF-7), prostate cancer (PC-3) and endometrial cancer (Ishikawa) cells: profile analysis of extracts. *Food Chem* **116**, 702–708.
61. Seyhan MF, Yilmaz E, Timirci-Kahraman Ö, *et al.* (2017) Anatolian honey is not only sweet but can also protect from breast cancer: elixir for women from Artemis to present. *IUBMB Life* **69**, 677–688.
62. Wen CTP, Hussein SZ, Abdullah S, *et al.* (2012) Gelam and nenas honeys inhibit proliferation of HT 29 colon cancer cells by inducing DNA damage and apoptosis while suppressing inflammation. *Asian Pac J Cancer Prev* **13**, 1605–1610.
63. Tahir AA, Sani NFA, Murad NA, *et al.* (2015) Combined ginger extract & gelam honey modulate Ras/ERK and PI3K/AKT pathway genes in colon cancer HT29 cells. *Nutr J* **14**, 31.
64. Wee LH, Morad NA, Aan GJ, *et al.* (2015) Mechanism of chemoprevention against colon cancer cells using combined gelam honey and ginger extract via mTOR and Wnt/ $\beta$ -catenin pathways. *Asian Pac J Cancer Prev* **16**, 6549–6556.
65. Hakim L, Alias E, Makpol S, *et al.* (2014) Gelam honey and ginger potentiate the anti cancer effect of 5-FU against HCT 116 colorectal cancer cells. *Asian Pac J Cancer Prev* **15**, 4651–4657.
66. Moskwa J, Borawska MH, Markiewicz-Zukowska R, *et al.* (2014) Polish natural bee honeys are anti-proliferative and anti-metastatic agents in human glioblastoma multiforme U87MG cell line. *PLOS ONE* **9**, e90533.
67. Aliyu M, Odunola OA, Farooq AD, *et al.* (2012) Acacia honey modulates cell cycle progression, pro-inflammatory cytokines and calcium ions secretion in PC-3 cell line. *J Cancer Sci Ther* **4**, 401–407.
68. Salleh MAM, Eshak Z & Ismail WIW (2017) Acacia honey induces apoptosis in human breast adenocarcinoma cell lines (MCF-7). *J Teknol* **79**, 9–16.
69. Afrin S, Giampieri F, Cianciosi D, *et al.* (2019) Strawberry tree honey as a new potential functional food. Part 1: Strawberry tree honey reduces colon cancer cell proliferation and colony formation ability, inhibits cell cycle and promotes apoptosis by regulating EGFR and MAPKs signaling pathways. *J Funct Foods* **57**, 439–452.
70. Ghashm AA, Othman NH, Khattak MN, *et al.* (2010) Antiproliferative effect of tualang honey on oral squamous cell carcinoma and osteosarcoma cell lines. *BMC Complement Altern Med* **10**, 49.
71. Fauzi AN, Norazmi MN & Yaacob NS (2011) Tualang honey induces apoptosis and disrupts the mitochondrial membrane potential of human breast and cervical cancer cell lines. *Food Chem Toxicol* **49**, 871–878.
72. Man N, Khuzaimi NM, Hassan R, *et al.* (2015) Antileukemic effect of tualang honey on acute and chronic leukemia cell lines. *Biomed Res Int* **2015**, 307094.
73. Yaacob NS, Nengsih A & Norazmi M (2013) Tualang honey promotes apoptotic cell death induced by tamoxifen in breast cancer cell lines. *Evid Based Complement Alternat Med* **2013**, 989841.
74. Jaganathan SK & Mandal M (2010) Involvement of non-protein thiols, mitochondrial dysfunction, reactive oxygen species and p53 in honey-induced apoptosis. *Invest New Drugs* **28**, 624–633.
75. Morales P & Haza AI (2013) Antiproliferative and apoptotic effects of Spanish honeys. *Pharmacogn Mag* **9**, 231–237.
76. Kassim M, Achoui M, Mustafa MR, *et al.* (2010) Ellagic acid, phenolic acids, and flavonoids in Malaysian honey extracts demonstrate *in vitro* anti-inflammatory activity. *Nutr Res* **30**, 650–659.
77. Hassan MI, Mabrouk GM, Shehata HH, *et al.* (2012) Antineoplastic effects of bee honey and *Nigella sativa* on hepatocellular carcinoma cells. *Integr Cancer Ther* **11**, 354–363.
78. Hanaa MR & Shaymaa MMY (2011) Enhancement of the antitumor effect of honey and some of its extracts using adiponectin hormone. *Aust J Basic Appl Sci* **5**, 100–108.
79. Haza AI & Morales P (2013) Spanish honeys protect against food mutagen-induced DNA damage. *J Sci Food Agric* **93**, 2995–3000.
80. Afrin S, Giampieri F, Gasparini M, *et al.* (2018) The inhibitory effect of manuka honey on human colon cancer HCT-116 and LoVo cell growth. Part 2: Induction of oxidative stress, alteration of mitochondrial respiration and glycolysis, and suppression of metastatic ability. *Food Funct* **9**, 2158–2170.
81. Afrin S, Forbes-Hernández TY, Cianciosi D, *et al.* (2019) Strawberry tree honey as a new potential functional food. Part 2: Strawberry tree honey increases ROS generation by suppressing Nrf2-ARE and NF- $\kappa$ B signaling pathways and decreases metabolic phenotypes and metastatic activity in colon cancer cells. *J Funct Foods* **57**, 477–487.
82. Liu J-R, Ye Y-L, Lin T-Y, *et al.* (2013) Effect of floral sources on the antioxidant, antimicrobial, and anti-inflammatory activities of honeys in Taiwan. *Food Chem* **139**, 938–943.



83. Aziz AA, Rady HM, Amer MA, *et al.* (2009) Effect of some honey bee extracts on the proliferation, proteolytic and gelatinolytic activities of the hepatocellular carcinoma Hepg2 cell line. *Aus J Basic Appl Sci* **3**, 2754–2769.
84. Yazan LS, Zali M, Shyfiq MF, *et al.* (2016) Chemopreventive properties and toxicity of kelulut honey in Sprague Dawley rats induced with azoxymethane. *Biomed Res Int* **2016**, 4036926.
85. Jaganathan SK, Mondhe D, Wani ZA, *et al.* (2010) Effect of honey and eugenol on Ehrlich ascites and solid carcinoma. *Biomed Res Int* **2010**, 989163.
86. Jaganathan SK, Mondhe D, Wani ZA, *et al.* (2014) Evaluation of selected honey and one of its phenolic constituent eugenol against L1210 lymphoid leukemia. *Sci World J* **2014**, 912051.
87. El-kott AF, Kandeel AA, El-Aziz SFA, *et al.* (2012) Anti-tumor effects of bee honey on PCNA and P53 expression in the rat hepatocarcinogenesis. *Int J Cancer Res* **8**, 130–139.
88. Moniruzzaman M, Sulaiman SA, Khalil MI, *et al.* (2013) Evaluation of physicochemical and antioxidant properties of sourwood and other Malaysian honeys: a comparison with manuka honey. *Chemistry Cent J* **7**, 138.
89. Fukuda M, Kobayashi K, Hirono Y, *et al.* (2011) Jungle honey enhances immune function and antitumor activity. *Evid Based Complement Alternat Med* **2011**, 908743.
90. Kadir EA, Sulaiman SA, Yahya NK, *et al.* (2013) Inhibitory effects of tualang honey on experimental breast cancer in rats: a preliminary study. *Asian Pac J Cancer Prev* **14**, 2249–2254.
91. Ahmed S, Sulaiman SA & Othman NH (2017) Oral administration of tualang and manuka honeys modulates breast cancer progression in Sprague–Dawley rats model. *Evid Based Complement Alternat Med* **2017**, 5904361.
92. Orsolić N, Knezević A, Sver L, *et al.* (2003) Influence of honey bee products on transplantable murine tumours. *Vet Comp Oncol* **1**, 216–226.
93. Swellam T, Miyanaga N, Onozawa M, *et al.* (2003) Antineoplastic activity of honey in an experimental bladder cancer implantation model: *in vivo* and *in vitro* studies. *Int J Urol* **10**, 213–219.
94. Tomasin R & Cintra Gomes-Marcondes MC (2011) Oral administration of aloe vera and honey reduces Walker tumour growth by decreasing cell proliferation and increasing apoptosis in tumour tissue. *Phytother Res* **25**, 619–623.
95. Attia WY, Gabry MS, El-Shaikh KA, *et al.* (2008) The anti-tumor effect of bee honey in Ehrlich ascite tumor model of mice is coincided with stimulation of the immune cells. *Egypt J Immunol* **15**, 169–183.
96. Hegazi AG, Abdel-Rahman EH, Abd-Allah F, *et al.* (2015) Influence of honey on immune status in mice-bearing Ehrlich carcinoma. *J Clin Cell Immunol* **6**, 295.
97. Mabrouk GM, Moselhy SS, Zohny SF, *et al.* (2002) Inhibition of methylnitrosourea (MNU) induced oxidative stress and carcinogenesis by orally administered bee honey and Nigella grains in Sprague Dawley rats. *J Exp Clin Cancer Res* **21**, 341–346.
98. Rao S, Hegde SK, Rao P, *et al.* (2017) Honey mitigates radiation-induced oral mucositis in head and neck cancer patients without affecting the tumor response. *Foods* **6**, E77.
99. Cho HK, Jeong YM, Lee HS, *et al.* (2015) Effects of honey on oral mucositis in patients with head and neck cancer: a meta-analysis. *Laryngoscope* **125**, 2085–2092.
100. Hawley P, Hovan A, McGahan CE, *et al.* (2014) A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. *Support Care Cancer* **22**, 751–761.
101. Charalambous M, Raftopoulos V, Paikousis L, *et al.* (2018) The effect of the use of thyme honey in minimizing radiation-induced oral mucositis in head and neck cancer patients: a randomized controlled trial. *Eur J Oncol Nurs* **34**, 89–97.
102. Xu JL, Xia R, Sun ZH, *et al.* (2016) Effects of honey use on the management of radio/chemotherapy-induced mucositis: a meta-analysis of randomized controlled trials. *Int J Oral Maxillofac Surg* **45**, 1618–1625.
103. Fogh SE, Deshmukh S, Berk LB, *et al.* (2017) A randomized phase 2 trial of prophylactic manuka honey for the reduction of chemoradiation therapy-induced esophagitis during the treatment of lung cancer: results of NRG Oncology RTOG 1012. *Int J Radiat Oncol Biol Phys* **97**, 786–796.
104. Mofid B, Rezaeizadeh H, Termos A, *et al.* (2014) Effect of processed honey and royal jelly on cancer-related fatigue: a double-blind randomized clinical trial. *Electronic Physician* **8**, 2475–2482.
105. Hizan NS, Hassan NHM, Haron J, *et al.* (2018) Tualang honey adjunct with anastrozole improve parenchyma enhancement of breast tissue in breast cancer patients: a randomized controlled trial. *Integr Med Res* **7**, 322–327.
106. Chan CW, Deadman BJ, Manley-Harris M, *et al.* (2013) Analysis of the flavonoid component of bioactive New Zealand mānuka (*Leptospermum scoparium*) honey and the isolation, characterisation and synthesis of an unusual pyrrole. *Food Chem* **141**, 1772–1781.
107. Khalil MI, Alam N, Moniruzzaman M, *et al.* (2011) Phenolic acid composition and antioxidant properties of Malaysian honeys. *J Food Sci* **76**, C921–C928.
108. Ahmed S & Othman NH (2013) Review of the medicinal effects of tualang honey and a comparison with manuka honey. *Malays J Med Sci* **20**, 6–13.
109. Czyżewska U, Siemionow K, Zaręba I, *et al.* (2016) Proapoptotic activity of propolis and their components on human tongue squamous cell carcinoma cell line (CAL-27). *PLOS ONE* **11**, e0157091.
110. Chen K-S, Shi M-D, Chien C-S, *et al.* (2014) Pinocembrin suppresses TGF- $\beta$ 1-induced epithelial-mesenchymal transition and metastasis of human Y-79 retinoblastoma cells through inactivating  $\alpha$ v $\beta$ 3 integrin/FAK/p38 $\alpha$  signaling pathway. *Cell Biosci* **4**, 41.
111. Chen Z, Rasul A, Zhao C, *et al.* (2013) Antiproliferative and apoptotic effects of pinocembrin in human prostate cancer cells. *Bangladesh J Pharmacol* **8**, 255–262.
112. Alday E, Valencia D, Carreño AL, *et al.* (2015) Apoptotic induction by pinobanksin and some of its ester derivatives from *Sonoran propolis* in a B-cell lymphoma cell line. *Chem Biol Interact* **242**, 35–44.
113. Sassi A, Maatouk M, Bzēouich IM, *et al.* (2018) Chrysin, a natural and biologically active flavonoid suppresses tumor growth of mouse B16F10 melanoma cells: *in vitro* and *in vivo* study. *Chem Biol Interact* **283**, 10–19.
114. Maasomi ZJ, Soltanahmadi YP, Dadashpour M, *et al.* (2017) Synergistic anticancer effects of silibinin and chrysin in T47D breast cancer cells. *Asian Pac J Cancer Prev* **18**, 1283–1287.
115. Yu X-M, Phan T, Patel PN, *et al.* (2013) Chrysin activates Notch1 signaling and suppresses tumor growth of anaplastic thyroid carcinoma *in vitro* and *in vivo*. *Cancer* **119**, 774–781.
116. Lin Y-M, Chen C-I, Hsiang Y-P, *et al.* (2018) Chrysin attenuates cell viability of human colorectal cancer cells through autophagy induction unlike 5-fluorouracil/oxaliplatin. *Int J Mol Sci* **19**, E1763.
117. Xu Y, Tong Y, Ying J, *et al.* (2018) Chrysin induces cell growth arrest, apoptosis, and ER stress and inhibits the activation of STAT3 through the generation of ROS in bladder cancer cells. *Oncol Lett* **15**, 9117–9125.



118. Ryu S, Lim W, Bazer FW, *et al.* (2017) Chrysin induces death of prostate cancer cells by inducing ROS and ER stress. *J Cell Physiol* **232**, 3786–3797.
119. Wang J, Wang H, Sun K, *et al.* (2018) Chrysin suppresses proliferation, migration, and invasion in glioblastoma cell lines via mediating the erk/nrf2 signaling pathway. *Drug Des Devel Ther* **12**, 721–733.
120. Celińska-Janowicz K, Zaręba I, Lazarek U, *et al.* (2018) Constituents of propolis: chrysin, caffeic acid, *p*-coumaric acid, and ferulic acid induce PRODH/POX-dependent apoptosis in human tongue squamous cell carcinoma cell (CAL-27). *Front Pharmacol* **9**, 336.
121. Yang B, Huang J, Xiang T, *et al.* (2014) Chrysin inhibits metastatic potential of human triple-negative breast cancer cells by modulating matrix metalloproteinase-10, epithelial to mesenchymal transition, and PI3K/Akt signaling pathway. *J Appl Toxicol* **34**, 105–112.
122. Zhang W, Tang B, Huang Q, *et al.* (2013) Galangin inhibits tumor growth and metastasis of B16F10 melanoma. *J Cell Biochem* **114**, 152–161.
123. Wang H-X & Tang C (2017) Galangin suppresses human laryngeal carcinoma via modulation of caspase-3 and AKT signaling pathways. *Oncol Rep* **38**, 703–714.
124. Cao J, Wang H, Chen F, *et al.* (2016) Galangin inhibits cell invasion by suppressing the epithelial-mesenchymal transition and inducing apoptosis in renal cell carcinoma. *Mol Med Rep* **13**, 4238–4244.
125. Zou W-W & Xu S-P (2018) Galangin inhibits the cell progression and induces cell apoptosis through activating PTEN and caspase-3 pathways in retinoblastoma. *Biomed Pharmacother* **97**, 851–863.
126. Choi YJ, Lee YH & Lee S-T (2015) Galangin and kaempferol suppress phorbol-12-myristate-13-acetate-induced matrix metalloproteinase-9 expression in human fibrosarcoma HT-1080 cells. *Mol Cells* **38**, 151–155.
127. Huang H, Chen AY, Rojanasakul Y, *et al.* (2015) Dietary compounds galangin and myricetin suppress ovarian cancer cell angiogenesis. *J Funct Foods* **15**, 464–475.
128. Yu S, Gong L-s, Li N-f, *et al.* (2018) Galangin (GG) combined with cisplatin (DDP) to suppress human lung cancer by inhibition of STAT3-regulated NF- $\kappa$ B and Bcl-2/Bax signaling pathways. *Biomed Pharmacother* **97**, 213–224.
129. Kumar R & Tiku AB (2018) Galangin induces cell death by modulating the expression of glyoxalase-1 and Nrf-2 in HeLa cells. *Chem Biol Interact* **279**, 1–9.
130. Xu YX, Wang B & Zhao XH (2017) *In vitro* effects and the related molecular mechanism of galangin and quercetin on human gastric cancer cell line (SGC-7901). *Pak J Pharm Sci* **30**, 1279–1287.
131. Wang Y, Wu J, Lin B, *et al.* (2014) Galangin suppresses HepG2 cell proliferation by activating the TGF- $\beta$  receptor/Smad pathway. *Toxicology* **326**, 9–17.
132. Su L, Chen X, Wu J, *et al.* (2013) Galangin inhibits proliferation of hepatocellular carcinoma cells by inducing endoplasmic reticulum stress. *Food Chem Toxicol* **62**, 810–816.
133. Han K, Lang T, Zhang Z, *et al.* (2018) Luteolin attenuates Wnt signaling via upregulation of FZD6 to suppress prostate cancer stemness revealed by comparative proteomics. *Sci Rep* **8**, 8537.
134. Anson DM, Wilcox RM, Huseman ED, *et al.* (2018) Luteolin decreases epidermal growth factor receptor-mediated cell proliferation and induces apoptosis in glioblastoma cell lines. *Basic Clin Pharmacol Toxicol* **123**, 678–686.
135. Wang S-W, Chen Y-R, Chow J-M, *et al.* (2018) Stimulation of Fas/FasL-mediated apoptosis by luteolin through enhancement of histone H3 acetylation and c-Jun activation in HL-60 leukemia cells. *Mol Carcinog* **57**, 866–877.
136. Fu J, Chen D, Zhao B, *et al.* (2012) Luteolin induces carcinoma cell apoptosis through binding Hsp90 to suppress constitutive activation of STAT3. *PLOS ONE* **7**, e49194.
137. Sonoki H, Tanimae A, Endo S, *et al.* (2017) Kaempferol and luteolin decrease claudin-2 expression mediated by inhibition of STAT3 in lung adenocarcinoma A549 cells. *Nutrients* **9**, E597.
138. Song S, Su Z, Xu H, *et al.* (2017) Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1. *Cell Death Dis* **8**, e2612.
139. Aneknan P, Kukongviriyapan V, Prawan A, *et al.* (2014) Luteolin arrests cell cycling, induces apoptosis and inhibits the JAK/STAT3 pathway in human cholangiocarcinoma cells. *Asian Pac J Cancer Prev* **15**, 5071–5076.
140. Hong J, Fristiody A, Nguyen CH, *et al.* (2018) Apigenin and luteolin attenuate the breaching of MDA-MB231 breast cancer spheroids through the lymph endothelial barrier *in vitro*. *Front Pharmacol* **9**, 220.
141. Yang M-Y, Wang C-J, Chen N-F, *et al.* (2014) Luteolin enhances paclitaxel-induced apoptosis in human breast cancer MDA-MB-231 cells by blocking STAT3. *Chem Biol Interact* **213**, 60–68.
142. Huang X, Dai S, Dai J, *et al.* (2015) Luteolin decreases invasiveness, deactivates STAT3 signaling, and reverses interleukin-6 induced epithelial-mesenchymal transition and matrix metalloproteinase secretion of pancreatic cancer cells. *Oncotargets Ther* **8**, 2989–3001.
143. Feng X-Q, Rong L-W, Wang R-X, *et al.* (2018) Luteolin and sorafenib combination kills human hepatocellular carcinoma cells through apoptosis potentiation and JNK activation. *Oncol Lett* **16**, 648–653.
144. Gong C, Yang Z, Zhang L, *et al.* (2018) Quercetin suppresses DNA double-strand break repair and enhances the radiosensitivity of human ovarian cancer cells via p53-dependent endoplasmic reticulum stress pathway. *Oncotargets Ther* **11**, 17–27.
145. Calgarotto AK, Maso V, Junior GCF, *et al.* (2018) Antitumor activities of quercetin and green tea in xenografts of human leukemia HL60 cells. *Sci Rep* **8**, 3459.
146. Granato M, Rizzello C, Montani MSG, *et al.* (2017) Quercetin induces apoptosis and autophagy in primary effusion lymphoma cells by inhibiting PI3K/AKT/mTOR and STAT3 signaling pathways. *J Nutr Biochem* **41**, 124–136.
147. Mukherjee A, Khuda-Bukhsh AR (2015) Quercetin down-regulates IL-6/STAT-3 signals to induce mitochondrial-mediated apoptosis in a non-small-cell lung-cancer cell line, A549. *J Pharmacopuncture* **18**, 19–26.
148. Chen Z, Huang C, Ma T, *et al.* (2018) Reversal effect of quercetin on multidrug resistance via FZD7/ $\beta$ -catenin pathway in hepatocellular carcinoma cells. *Phytomedicine* **43**, 37–45.
149. Yu D, Ye T, Xiang Y, *et al.* (2017) Quercetin inhibits epithelial-mesenchymal transition, decreases invasiveness and metastasis, and reverses IL-6 induced epithelial-mesenchymal transition, expression of MMP by inhibiting STAT3 signaling in pancreatic cancer cells. *Oncotargets Ther* **10**, 4719–4729.
150. Ding Y, Chen X, Wang B, *et al.* (2018) Quercetin suppresses the chymotrypsin-like activity of proteasome via inhibition of MEK1/ERK1/2 signaling pathway in hepatocellular carcinoma HepG2 cells. *Can J Physiol Pharm* **96**, 521–526.
151. Li N, Sun C, Zhou B, *et al.* (2014) Low concentration of quercetin antagonizes the cytotoxic effects of anti-neoplastic drugs in ovarian cancer. *PLOS ONE* **9**, e100314.

152. Feng J, Song D, Jiang S, *et al.* (2018) Quercetin restrains TGF- $\beta$ 1-induced epithelial–mesenchymal transition by inhibiting Twist1 and regulating E-cadherin expression. *Biochem Biophys Res Commun* **498**, 132–138.
153. Wang R, Yang L, Li S, *et al.* (2018) Quercetin inhibits breast cancer stem cells via downregulation of aldehyde dehydrogenase 1A1 (ALDH1A1), chemokine receptor type 4 (CXCR4), mucin 1 (MUC1), and epithelial cell adhesion molecule (EpCAM). *Med Sci Monit* **24**, 412–420.
154. Rasul A, Millimouno FM, Ali Eltayb W, *et al.* (2013) Pinocembrin: a novel natural compound with versatile pharmacological and biological activities. *Biomed Res Int* **2013**, 379850.
155. Trakoontivakorn G, Nakahara K, Shinmoto H, *et al.* (2001) Structural analysis of a novel antimutagenic compound, 4-hydroxypanduratin A, and the antimutagenic activity of flavonoids in a Thai spice, fingerroot (*Boesenbergia pandurata* Schult.) against mutagenic heterocyclic amines. *J Agric Food Chem* **49**, 3046–3050.
156. Hsu C-L, Yu Y-S & Yen G-C (2010) Anticancer effects of *Alpinia pricei* Hayata roots. *J Agric Food Chem* **58**, 2201–2208.
157. Kumar MAS, Nair M, Hema PS, *et al.* (2007) Pinocembrin triggers Bax-dependent mitochondrial apoptosis in colon cancer cells. *Mol Carcinog* **46**, 231–241.
158. Samarghandian S, Afshari JT & Davoodi S (2011) Chrysin reduces proliferation and induces apoptosis in the human prostate cancer cell line pc-3. *Clinics* **66**, 1073–1079.
159. Russo A, Longo R & Vanella A (2002) Antioxidant activity of propolis: role of caffeic acid phenethyl ester and galangin. *Fitoterapia* **73**, S21–S29.
160. Heo MY, Sohn SJ & Au WW (2001) Anti-genotoxicity of galangin as a cancer chemopreventive agent candidate. *Mutat Res Rev Mutat Res* **488**, 135–150.
161. Liu D, You P, Luo Y, *et al.* (2018) Galangin induces apoptosis in MCF-7 human breast cancer cells through mitochondrial pathway and phosphatidylinositol 3-kinase/Akt inhibition. *Pharmacology* **102**, 58–66.
162. Lee C-C, Lin M-L, Meng M, *et al.* (2018) Galangin induces p53-independent S-phase arrest and apoptosis in human nasopharyngeal carcinoma cells through inhibiting PI3K-AKT signaling pathway. *Anticancer Res* **38**, 1377–1389.
163. Hayes G, Wright N, Gardner SL, *et al.* (2018) Manuka honey and methylglyoxal increase the sensitivity of *Staphylococcus aureus* to linezolid. *Lett Appl Microbiol* **66**, 491–495.
164. Paramita D & Wisnubroto JDP (2018) Effect of methylglyoxal on reactive oxygen species, KI-67, and caspase-3 expression in MCF-7 cells. *Exp Mol Pathol* **105**, 76–80.
165. Du J, Suzuki H, Nagase F, *et al.* (2000) Methylglyoxal induces apoptosis in Jurkat leukemia T cells by activating c-Jun N-terminal kinase. *J Cell Biochem* **77**, 333–344.
166. Chan W-H, Wu H-J & Shiao N-H (2007) Apoptotic signaling in methylglyoxal-treated human osteoblasts involves oxidative stress, c-Jun N-terminal kinase, caspase-3, and p21-activated kinase 2. *J Cell Biochem* **100**, 1056–1069.
167. Ghosh A, Bera S, Ray S, *et al.* (2011) Methylglyoxal induces mitochondria-dependent apoptosis in sarcoma. *Biochemistry (Mosc)* **76**, 1164–1171.
168. Tuorkey MJ (2016) Molecular targets of luteolin in cancer. *Eur J Cancer Prev* **25**, 65–76.
169. Ward AB, Mir H, Kapur N, *et al.* (2018) Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. *World J Surg Oncol* **16**, 108.
170. Li S, Yuan S, Zhao Q, *et al.* (2018) Quercetin enhances chemotherapeutic effect of doxorubicin against human breast cancer cells while reducing toxic side effects of it. *Biomed Pharmacother* **100**, 441–447.
171. Li X, Zhou N, Wang J, *et al.* (2018) Quercetin suppresses breast cancer stem cells (CD44<sup>+</sup>/CD24<sup>-</sup>) by inhibiting the PI3K/Akt/mTOR-signaling pathway. *Life Sci* **196**, 56–62.